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Abstract
The work for this project was carried out in two parts. The first part of this project 
describes, evaluates, and compares a new pre-production automated analyser with the 
manual Pierce affinity method for the measurement of glycohaemoglobin (GHb). The Pierce 
affinity method has proven reliable for the measurement of GHb, but is very labour intensive 
requiring several hours for the completion of the test. The alternative new GHb analyser 
is simple and rapid to use.
The automated method is also more precise (CV < 5%) and is less prone to error 
than the manual assay. There was a good correlation between the two methods ( n = 50, y = 
1.018x -0.1034, r = 0.9806 where y = Drew x = Pierce, p = < 0.0001 using the assigned 
cahbrant values of BRI = 3.8%, BR2 = 10.0%. As a result of these investigations, we have 
now replaced our manual method with the automated analyser. Towards the end of this 
project we came under pressure from our endocrinologist to report our GHb results as 
DCCT aligned'. To this end we used the Primus DCCT aligned calibrants (intended for their 
own analyser) with values of Primus 1 = 5.8%, Primus 2 = 13.3%. The results of the 
correlation study of Biorad versus Primus calibrants was n=  139, y = 0.7585x + 2.0154, r =
0.9981 where y = Primus (GHb%) x = Biorad GHb (%), p = < 0.001.
The second part of this project was an evaluation of the effect of continuous 
ambulatory peritoneal dialysis (CAPD) treatment on GHb results. The peritoneal dialysis 
solutions used in CAPD contain from 13.6 g to 38.6 g/1 of glucose as an osmotic agent. 
During CAPD 100-200 g of glucose is absorbed from the glucose-containing dialysate 
fluids each day. Icodextrin is a starch-derived glucose polymer which also acts as an 
osmotic agent when administered intraperitoneally for CAPD, but unlike glucose-containing 
CAPD fluids does not contribute to large amounts of glucose absorption. The GHb 
measurement for this part of the evaluation was carried out using the Drew Scientific GHb- 
100 analyser after the first part of the project was successfully completed.
Contrary to what was expected CAPD did not cause a statistically significant 
difference in the concentration of GHb of non-diabetic patients compared to a non-diabetic 
group of patients who were not subjected to CAPD.
The research conformed to the ethical standards set out by the Royal Sussex County 
Hospital for research.
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1.0 INTRODUCTION
Glycohaemoglobin measurement is a test which is valuable in the monitoring and 
treatment of hyperglycaemic patients. Hyperglycaemia occurs in patients with diabetes 
mellitus and is reported to occur in non-diabetic renal patients on continuous ambulatory 
peritoneal dialysis (CAPD) who are dialysed with a high glucose content fluid (1). Both 
these conditions are discussed in detail.
1.1 Diabetes Mellitus
Diabetes Mellitus is a group of metabolic disorders characterised by chronic 
hyperglycaemia due to relative insulin deficiency, resistance or both. It is common and 
effects 30 million people world wide. Diabetes is usually irreversible, and although patients 
have a reasonably normal life-style, its late complications result in a reduced life-expectancy 
and considerable uptake of health resources. Macrovascular disease leads to an increased 
prevalence of coronary artery disease, peripheral vascular disease and stroke, while 
microvascular damage results in diabetic retinopathy and contributes to nephropathy (2).
1.1.1 Types of Diabetes Mellitus
Diabetes may be primary or secondary. Primary diabetes include:- type I or insulin - 
dependent diabetes mellitus (IDDM); type II or non-insulin-dependent diabetes mellitus 
(NIDDM); and the much rarer types of diabetes usually associated with other hereditary 
disorders. Secondary diabetes include diabetes due to destruction of the pancreas by drugs, 
disease or surgery and disease due to hormonal imbalance (3).
1) Type I Diabetes (Insulin-Dependent)
Insulin-dependent diabetes mellitus (IDDM) identifies patients who cannot survive 
without insulin treatment. The commonest cause is autoimmune destruction of the beta-cells 
of the islets of Langerhans. Insulin deficiency is so profound that ketoacidosis - the hallmark
of IDDM - will develop unless insulin replacement is given (3). The prevalence of IDDM 
shows a marked geographical variation with a 35-fold difference between Finland and 
Japan, the countries with the highest and lowest frequencies. In the UK the prevalence is 
about 0.25% and it accounts for about 20% of diabetes (2) Most patients present young 
and the peak age of onset is 12 years. At least 10% of diabetic patients aged over 65 years 
are insulin-dependent (3).
Type I diabetes is due to an interaction between environmental factors and a genetic 
predisposition to the disease. Inheritance is polygenic; major susceptibility loci include the 
human leucocyte antigen (HLA) class II genes (chromosome 6p) and the insulin gene 
(chromosome 1 Ip). Possible environmental triggers for IDDM include various viruses (e.g. 
coxsackie) and neonatal exposure to bovine serum albumin in cows milk (2). Putative beta­
cell autoantigens that might incite immune damage include glutamic acid decarboxylase 
(GAD) and insulin. Circulating antibodies against these and other antigens are detectable in 
most newly presenting IDDM patients, and also in some subjects with apparently typical 
NIDDM (2). The development of IDDM is the culmination of beta-cell destruction, often 
over many years. During the asymptomatic pre-diabetic phase, various beta-cell 
autoantibodies are present and subtle abnormalities of insulin secretion and glucose 
tolerance can be detected (2).
IDDM usually presents acutely with osmotic symptoms due to hyperglycaemia 
(thirst, polyuria, polydipsia), tiredness and weight loss. Minor symptoms include cramps, 
blurred vision and superficial infections. Nausea, vomiting and drowsiness usually denote 
impending ketoacidosis which nowadays only affects about 5-10% of newly diagnosed 
patients (3). Correction of hyperglycaemia (this impairs remaining beta-cell function) may 
induce a remission (honeymoon period) during which insulin requirements are low. 
Remission ends, sometimes after many months, when remaining beta-cells are destroyed by 
continuing autoimmune activity (2).
40-50% of patients with long-standing IDDM are at risk of significant microvascular 
complications (retinopathy, neuropathy, nephropathy), which are specific for diabetes, or 
macrovascular disease (atheroma). Evidence shows unequivocally that good glycaemic 
control prevents the specific diabetes-related complications (3). Overall mortality in IDDM 
is increased 4-7 fold compared with matched non-diabetic population, principally because of 
premature death from renal failure and coronary heart disease (3).
More accurate methods are being developed to predict which at-risk individuals will 
develop IDDM. Agents such as nicotinamide which protect against beta-cell damage, may 
be able to induce prolonged remission, or even prevent the development of IDDM (2).
2) Type n  Diabetes (Non-Insulin-Dependent)
Non-insulin-dependent diabetes mellitus (NIDDM) identifies patients who do not 
need insulin treatment to survive, though they may need insulin in order to remain healthy 
(about 20% are insulin treated) (3). It is characterised by variable combinations of insulin 
resistance and insulin deficiency; the latter is less severe than in IDDM, and blood levels 
remain high enough to prevent excessive lipolysis and spontaneous ketoacidosis. Patients 
with NIDDM are therefore C-peptide positive (2).
NIDDM accounts for up to 85% of the diabetic population in most countries, 
affecting 5-7% of Western populations and 10% of people over the age of 70 years. The 
prevalence is often low in developing countries (<1%) and very high (40-50%) in certain 
groups which have undergone rapid Westernisation (e.g. Pima Indians in North America). It 
is becoming steadily more common in many countries. The peak age of onset is 60 years; 
most subjects are diagnosed after the age of forty years (3).
Genetic factors determine most of the susceptibility to the common type of NIDDM. 
Thrifty susceptibility genes', postulated to favour energy storage, might favour survival 
during harsh conditions but could lead to obesity, insulin resistance and NIDDM when food
is freely available. 'Thrifty genes' could act by inducing insulin resistance in the liver and 
muscle but not fat; their identity remains unknown (2).
Environmental factors contributing to the development of NIDDM include excessive 
energy intake and physical inactivity, which predispose to obesity and perhaps malnutrition 
in utero and infancy, which may impair beta-cell development. Diabetogenic drugs, 
pregnancy and excess counter-regulatory hormones can also induce NIDDM (2).
Obesity is present in over 50% of male and 70% of female patients and strongly 
predisposes to the disease. Truncal obesity, with visceral fat deposition, is particularly 
important in inducing insulin resistance and is associated with glucose intolerance, 
hypertension and dyslipidaemia (syndrome !X!; Raven’s Syndrome). Obesity may induce 
insulin restance through increased secretion of tissue necrosis factor alpha (TNFa)
Initially, insulin secretion rises and overcomes the effect of insulin resistance but 
ultimately fails and allows blood glucose levels to increase through a phase of impaired 
glucose tolerance (IGT) to overt NIDDM The cause of beta-cell failure is unknown. The 
beta-cell product, islet amyloid polypeptide (LAPP) or its amyloid product that is deposited 
in the islets, have been implicated (2).
NIDDM diagnosed in adolescence Maturity Onset Diabetes Mellitus in the Young' 
(MODY) has in some cases been associated with mutations in the gene coding for 
glucokinase which is important in regulating insulin secretion in response to ambient 
glucose levels. Mutations in mitochondrial DNA are responsible for rare maternally 
inherited syndromes of diabetes with various neuromuscular syndromes (3).
About 50% of NIDDM patients present with classical osmotic symptoms due to 
hyperglycaemia, but many are diagnosed fortuitously or later suffering from diabetes-related 
complications. NIDDM is insidious and often present for several years before diagnosis. Up 
to 50% of all cases may be as yet undiagnosed (3). NIDDM cause microvascular diabetic 
complications and macrovascular disease; the major cause of death is coronary heart disease
(60% of cases). Microvascular disease, especially retinopathy, may be established at the 
time of diagnosis. Overall 5-year mortality is increased two-to-three fold and life expectancy 
reduced by 5-10 years (3).
Management commences with diet and life style, with a low-fat, high complex 
carbohydrate diet (and a caloric restriction for obese patients) and increased physical 
activity. These measures are usually inadequate and a sulphonylurea (insulin secretagogue; 
more useful in non-obese patients) or the insulin-sensitising biguanide, metformin, is added. 
Many patients ultimately require both oral agents and subsequently insulin (3).
Adjunctive treatments include the alpha-glucosidase inhibitor, acarbose, and anti­
obesity drugs or very low calorie diets. Novel drugs include the thiazolidincdionic 
derivatives, e.g. troglitazone, which are insulin-resistance modulators (3).
1.1.1.1 Summary of Primary Diabetes (IDDM and NIDDM)
Table 1 Summary of Primary Diabetes (IDDM and NIDDM)
Type I (IDDM) Type II fNIDDM)
Common age of onset: Any, predominantly young Any, predominantly middle 
and older ages
Family history of diabetes: Uncommon Common
Seasonal incidence: More in winter months No seasonal preponderance
Phenotype: Thin Obese
Haplotypes: HLAB8, B15, B18, DR3, 
DR4, DQB, etc.
No preponderance
Onset: Rapid Slow
Symptoms: Severe Mild or absent
Urine: Glucose and acetone Glucose
Keto-acidosis: Prone Resistant
Serum insulin: Low or absent Usually depressed but 
may be raised
Islet cell antibodies: Present at onset Absent
Treatment: Insulin Diet
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Diabetes Associated with Other Genetic Disorders
Diabetes is sometimes a part of somewhat rare syndromes occurring in childhood 
and involving the neuro-endocrine and nervous system. Perhaps the least uncommon is the 
DIDMOAD syndrome. DIDMOAD is an acronym for diabetes insipidus, diabetes mellitus, 
optic atrophy and deafness. (Friedreich's ataxia, polyneuritis, retinitis pigmentosa, 
hypogonadism and obesity are other features sometimes involved). The genetic inheritance 
of these disorders can hardly be in question because they often occur in siblings or when the 
parents are consanguineous: The most likely explanation is that the syndrome is due to an 
inherited defect of embryonic neuroectoderm* from which primitive endocrine colls migrate 
to the gut and pancreas. There are many other associations with genetic disorders (3).
1.1.1.2 Secondary Diabetes
Secondary Diabetes results from destruction of the islets by surgery, disease or 
drugs. Table 2 shows a list of causes of secondary diabetes.
Table 2 Causes of secondary diabetes
Cause Example
Liver Disease Cirrhosis.
Pancreatic Disease Cystic fibrosis. Chronic pancreatitis. Pancreatectomy, 
Haemochromatosis, Carcinoma of the pancreas.
Endocrine Disease Cushings's syndrome, Acromegaly, Thyrotoxicosis, Pheochromocytoma, 
Glucogonoma.
Drug-Induced Disease Thiazide diuretics, Corticosteriod therapy.
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1.2 Renal Patients on CAPD Treatment
Chronic uraemia is associated with decreased glucose tolerance and other 
abnormalities reflecting impaired glucose metabolism (4-6). Fasting blood glucose levels 
are often normal or only moderately elevated but about 50% of the patients show an 
abnormal oral or intravenous glucose tolerance (4). Peripheral insulin resistance appears to 
be the most important pathogenetic factor for glucose intolerance in uraemia although 
decreased insulin secretion is observed in some patients (4-6). In addition, the basal 
circulating levels of many hormones including insulin and glucagon are often elevated, 
mainly due to their impaired degradation by the diseased kidneys (5). Other factors 
associated with end stage renal failure that are capable of interfering with glucose 
homeostasis are, accumulation of uraemic toxins, diminished physical activity, metabolic 
acidosis, hyperosmolality and medication (7).
During continuous ambulatory peritoneal dialysis (CAPD), which is an increasingly 
used form of chronic dialysis therapy, 2 litres of dialysis fluid remains in the patients 
abdomen at all times and are replaced with fresh fluid four to five times daily.' CAPD as 
currently used only replaces about 5-10% of the function of two normal kidneys: four 
exchanges of 2 litres each in a 24 hr period equals 8 litres/day, or 5-6 ml/min; 
ultrafiltration using hyperosmolar fluid to remove excess salt and water may raise the 
clearance to 7 ml/min. CAPD provides round-the-clock function in contrast to the 
intermittent function provided by haemodialysis, and the latter, averaged over a period of a 
week, gives a comparatively low clearance. With the use of glucose containing CAPD fluids 
100-200 g of glucose is absorbed each day from the dialysis fluid (8). In analogy with 
intermittent peritoneal dialysis (9) it is conceivable that such a continuous glucose load 
could result in further impairment of glucose tolerance by exhausting insulin secreting 
capacity.
After a glucose challenge  ^ concentrations of glycated plasma proteins continue to
rise even after return to normoglycaemia. Amadori products continued to form as glucose 
concentrations fall (10). Similar changes might take place in dialysis, therefore CAPD 
patients were considered a suitable group for study.
1.2.1 Glucose and Other Omotlc Agents in CAPD
In the peritoneal dialysis system, hydrostatic pressure in the blood compartment 
cannot be readily manipulated. Therefore, traditionally a solute (osmotic agent) is added to 
the peritoneal dialysis solution to create an osmotic driving force. During the process of 
ultrafiltration, the rate of ultrafiltration decreases with time due to dilution by the 
ultrafiltrate and absorption of the osmotic agent. Thus ultrafiltration will eventually cease 
after the dialysis solution is infused. The bigger the molecule of the osmotic agent, the 
longer the ultrafiltration lasts because solute absorption through the peritoneal membrane is 
slower. Thus, to achieve sustained ultrafiltration, an osmotic agent with a bigger, non-toxic, 
biocompatable molecule would be more advantageous than the smaller one at comparable 
osmotic gradients.
The osmotic driving force is dependent on the osmolality, which is a measure of the 
total number of osmotic agent molecules in the solution. It is directly related to the molal 
concentration of a solute, i.e., the number of moles per kilogram of solvent. In clinical 
practice, it is customary to measure the solute concentration as a percentage, i.e. actual 
weight per litre of solution. Large molecular weight solutes must be dissolved in higher 
percentage concentrations to obtain the same osmolality. The properties of charged 
molecules are different as the osmotic driving force does not depend on the polymer
molecules themselves, but on the concentration of ionised electrolytes.
Glucose, which is the only osmotic agent in common use for CAPD, readily 
permeates through the peritoneal membrane. Using an intraperitoneal volume marker, Pyle 
et al. characterised the ultrafiltration profile of glucose based solutions (11). They 
demonstrated a rapid exponential decline in the ultra filtration rate with time in response to
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a fall in osmotic gradient, due to a combination of glucose absorption and intraperitoneal 
dilution. Once equilibration of osmotic forces occurs, ultrafiltration ceased and reabsorption 
began. Since the equilibration times were between 2-3 hours with glucose solutions, the 
prolongation of the dwell time beyond this, commonly led to reabsorption of fluid that 
exceeded the ultrafiltrate (negative ultrafiltration); this was particularly noticeable in 
overnight exchanges.
Several authors have studied glucose absorption from glucose containing CAPD 
fluids. Lindholm et al. (12) studied glucose absorption from the dialysate in 13 non-diabetic 
patients undergoing metabolic studies. All patients exchanged 2 litres of dialysate four times 
per day. An average of 121 +/- 40 g glucose per day was absorbed each day representing an 
uptake of 71 +/- 10% of the glucose instilled in the peritoneal cavity.
Grodsteine et al. (13) found that an average of 182 +/- 61 g of glucose was 
absorbed each day. Most of their patients used five exchanges of dialysate per day. The 
percentage of the instilled glucose which was absorbed was 72%.
Baeyer et al. (14) found that the mean daily absorption of glucose was 117 +/- 14 
g/d (four exchanges per day), while Keusch et al. (15) have reported an uptake of 104 +/- 8 
g/d, and Splendiani et al. (16) an average uptake of 156 g/d.
Finally, De Santo et al. (17) have reported an average uptake of 271 +/- 5 g of 
glucose per day (five exchanges per day). These data show that under normal conditions 
most patients on CAPD absorb between 100 and 200 g of glucose per day, depending on 
the number of exchanges per day, the number of hypertonic solutions and the rate of 
absorption in the individual patient.
In addition, the continuous daily absorption of 100-200 grams of glucose from the 
dialysate imposed a substantial carbohydrate load, aggravating such long term metabolic 
complications as hyperinsulinaemia, hyperlipidaemia and obesity (18).
Lindholm et al. (12) and Breckenridge et al. (19) found an increase in high-density 
lipoprotein (HDL) cholesterol levels in previously normolipidaemic patients, and Chan et al.
(20) have reported higher levels of HDL cholesterol in CAPD patients than in patients 
treated with haemodialysis.
Lindholm et al. (12) and Khanna et al. (21) reported that serum triglycerides as 
well as cholesterol in all lipoprotein fractions tended to increase during the first 4-6 months 
of CAPD treatment. After 1 year these levels decreased again.
Baeyer et al. (14) found increased cholesterol levels and unchanged triglyceride 
levels after more than 6 months treatment. Keusch et al. (15) found increases in both serum 
triglycerides, serum cholesterol and HDL cholesterol after 9 months on CAPD. Turgan et 
al. (22) found increases in serum cholesterol levels but unchanged serum triglycerides in 
patients with restrictions of oral carbohydrate intake and a limited use of hypertonic 
solutions.
More recently the prolonged exposure to hyperosmolality has been implicated in the 
insidious damage to the peritoneum and host defences (23). These considerations have 
stimulated many investigators to search for an alternative osmotic agent with emphasis on 
correcting the metabolic and ultrafiltration deficiencies as well as achieving a more 
physiological solution capable of functioning over long dwell periods.
Various osmotic agents have been tried differing predominantly in their molecular
size. Eariy research workers concentrated on minimising the metabolic side effects of
glucose rather than altering the ultrafiltration profile; hence solutes of molecular size similar
to or smaller than glucose were utilised (Table 3). In the majority of cases the rate of
transperitoneal absorption exceeded the "metabolic" capacity resulting in serious
hyperosmolar syndromes (24-26). Whilst glycerol (27-29) and amino acids (30-31), have
had some long-term use, none of these have been found suitable for general use. Large
molecular weight substances have also been tried, to modify both the ultrafiltration profile
and limit metabolic side effects. Dextran (32), polyanions and gelatin (33) have had
limited human and animal experimentation with disappointing results related to relative
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insolubility, viscosity, allergenicity and accumulation in the body.
The lack of success in finding a suitable alternative agent, led to a re-examination of 
the fundamental role of osmotic forces in peritoneal dialysis. In biological systems, where 
water and solute requirements are similar to those on CAPD, the osmotic effectiveness of 
albumin (MW 68,000 Da) is well recognised. This physiological approach is based on the 
biological model of the permeable capillary wall, where only impermient solutes exert an 
osmotic force. The osmotic flow across such membrane is determined by the concentration 
gradient of impermient solutes rather than the difference in the total number of solutes 
across it, i.e. osmolality.
Albumin (human) is slowly absorbed from the peritoneal cavity, yields sustained 
ultrafiltration, and is non-toxic, non-immunogenic and readily metabolised. The proportion 
of bound to freely diflusible electrolytes in albumin solutions is known. However, the 
prohibitive cost of albumin renders it impractical for routine clinical use.
1.2.2 Glucose Polymers in CAPD
Whilst none of the above substances met the needs of an ideal osmotic agent the 
long dwell exchange of CAPD would be best met by a large molecular weight substance. 
The large size would limit the rate and amount of absorption from the peritoneal cavity thus 
giving sustained ultrafiltration. With selection of the substance of an appropriate reflection 
coefficient it would be possible to achieve ultrafiltration with solutions iso-osmotic to 
uraemic plasma. Glucose polymers could fulfill this role.
Icodextrin is a starch-derived glucose polymer which acts as an osmotic agent when 
administered intraperitoneally for continuous ambulatory peritoneal dialysis. A 7.5% w/v 
icodextrin solution is approximately iso-osmolar to serum but produces sustained 
ultrafiltration over a period of up to 12 hours in CAPD.
A randomised multicentre investigation of icodextrin in ambulatory peritoneal
dialysis (MIDAS) study group (34) was set up to evaluate the safety of icodextrin as an 
alternative osmotic agent to glucose in CAPD. MIDAS was the largest study of CAPD to 
have been conducted and has provided a wealth of information not only about the efficacy 
and safety of icodextrin and glucose, but also on morbidity in CAPD patients which had not 
been available before. About 5% of the U.K. CAPD population from eight major cities were 
included in the study.
The main aim of the study was to document the safety and tolerability of icodextrin 
in CAPD patients for six months, but its efficacy was also compared with glucose during the 
study. It demonstrated that the overnight use of icodextrin was well tolerated and produced 
ultrafiltration up to 5.5 times that of 1.36% glucose and was marginally better, though not 
significantly so, than the 3.86% glucose solution. In addition, there was lower carbohydrate 
absorption compared to the 3.86% glucose solution. Almost no patients had fluid resorption 
('negative ultrafiltration') overnight on icodextrin compared with about a quarter of the 
control patients on glucose containing CAPD fluids. There was no evidence of any 
tachyphylaxis to icodextrin.
Patients in both groups tolerated thdlr treatment well; the icodextrin group reported 
fewer adverse events than the control group. Cardiovascular disease accounted for most of 
the non-CAPD related adverse events. This is consistent with the high cardiovascular 
morbidity recorded at entry to MIDAS and the overall high level of cardiovascular disease 
in the CAPD population. Although there was a higher cardiovascular morbidity in the 
icodextrin group in entry, there was no excess cardiovascular morbidity during MIDAS.
The MIDAS study demonstrated the efficacy of icodextrin in CAPD patients. It 
suggested that icodextrin could replace glucose for the long dwell, particularly because of 
the sustained ultrafiltration it offers with the little likelihood of resorption of fluid from the 
peritoneum. It is at least as effective as high strength glucose (3.86%) and has potential 
advantages because it is iso-osmolar with uraemic serum (34).
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Table 4 shows the composition of a range of commercially available CAPD fluids from 
Baxter containing glucose (1.36%, 2.27%, 3.86%) and 7.5% icodextnn.
Table 3 Osmotic agents studied in CAPD patients (adapted from reference 35).
Agents Molecular 
weight (Da)
Charge Reported side-effects
Low molecular 
weight
Glucose 180 Nil Hyperlipidaemia, obesity, hyperinsulinaemia
Fructose 180 Nil Hypertriglyceridaemia; hyperosomolality
Sorbitol 180 Nil Hyperosmolality and retention
Xylitol 152 NU Lactic acidosis; hyperosmolality
Glycerol 92 Nil Short-lived ultrafiltration; glycerol related 
hyperosmolality
Amino-acids 100 - 200 +/- Manufacturing and cost problems; increase 
nitrogen load; no optimum profile
High molecular 
weight
Polyanions 40 000 - 90 000 - ve Toxic to peritoneum
Polycations 40 000 - 90 000 + ve Cardiovascular instability (rats)
Neutral
dextran
60 000 - 200 000 Nil Absorbed, intraperitoneal bleeding in rats 
ultrafiltration
Gelatine 20 000 - 350 000 +/- Prolonged half-life/ immunogenicity
Glucose
polymers
250 - 22 000 Nil Retention of maltose
Ideal osmotic 
agent
Albumin 68 000 - ve None - but is prohibitively expensive
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Table 4 Comparison of the composition a range of commercially available CAPD fluids
containing glucose (Dianeal from Baxter) and 7.5% w/v icodextrin (also from Baxter). 
(36,37)
Dianeal PD4 
with Glucose 
1.36%
Dianeal PD4 
with Glucose 
2.27%
Dianeal PD4 
with Glucose 
3.86%
Icodextrin 
7.5% w/v
Each one litre contains: 
Anhydrous Glucose 13.6 g 22.7 g 38.6-g
Anhydrous Icodextrin ---- ---- ----- 75 g
Sodium Chloride 5.4 g 5.4 g 5.4 g 5.4 g
Sodium Lactate 4.5 g 4.5 g 4.5 g 4.5 g
Calcium Chloride 184 mg 184 mg 184 mg 257 mg
Magnesuim Chloride 51 mg 51 mg 51 mg 51 mg
mmol per litre (approx.); 
Sodium 132 132 132 133
Calcium 1.25 1.25 1.25 1.75
Magnesium 0.25 0.25 0.25 0.25
Chloride 95 95 95 96
Lactate 40 40 40 40
mOsm per litre (approx.) 344 395 483 284
1.3 Diagnosis of Diabetes
The diagnosis is usually straight forward. Blood glucose is so closely controlled by 
the body that even small deviations become important.
1. In symptomatic patients, a single elevated blood glucose, measured by a reliable method, 
indicates diabetes. According to the World Health Organisation (WHO), a fasting venous 
plasma glucose of 8 mmol/1 (144 mg/dl) or more is diagnostic of diabetes mellitus. 
Alternatively, a random venous plasma glucose of 11.1 mmol/1 (200 mg/dl) or more 
establishes the diagnosis (2).
2. In asymptomatic or mildly symptomatic patients, the diagnosis is made on:
(a) One, preferably two, fasting venous blood glucose levels above 6.7 mmol/1 (120 
mg/dl), the equivalent venous plasma level is 7.8 mmol/1 (140 mg/dl), or
(b) One, preferably two, random values above 10 mmol/1 (180 mg/dl) in venous 
whole blood or 11.1 mmol/1 (200 mg/dl) in venous plasma.
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3. A glucose tolerance test (GTT) is unnecessary when the criteria above are satisfied, and 
should be reserved for true borderline cases.
4. Glycosuria is measured using sensitive glucose-specific dipstick methods. Glycosuria is 
not diagnostic of diabetes but indicates the need for further investigation. About 1% of the 
population have renal glycosuria in which there is a low renal threshold for glucose (2).
1.4 Measuring Control
1.4.1 Urine Tests
1.4.1.1 Urine Glucose Test
Until the advent of home blood glucose monitoring, urine glucose testing was the 
chief day-to-day method of assessing diabetic control, the rationale being that urine glucose 
reflects mean blood glucose levels over the time the urine was collected.
Glucose is freely filtered at the renal glomerulas and actively reabsorbed in the 
proximal tubule. The reabsorption is limited, the maximal limit being the renal glucose 
threshold, which is exceeded when the blood glucose concentration is, on average >10 
mmol/1. Glycosuria thus occurs when the blood glucose level exceeds 10 mmol/1, and from 
this point urine glucose concentrations should be proportional, to the increasing 
hyperglycaemia. Non-specific Benedict's reagent tests (Clinitest) and specific glucose 
oxidase strips (e.g. Clinistix) are available for urine glucose estimation.
Although urine testing is painless and less expensive than blood glucose monitoring, 
it is undesirable and misleading for several reasons (38).
1) The renal threshold is high in some individuals, such as those with long-standing 
diabetes, so that marked hyperglycaemia may exist without glycosuria.
2) The threshold is low in some people, such as in pregnancy and in children, so that 
glycosuria may occur with a normal blood glucose concentration.
3) The renal threshold varies between patients (including the above groups) but also 
changes in the same individual over time.
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4) Fluid intake and urine concentration affect urine results.
5) The result does not reflect the blood glucose level at the time of testing but the average 
over the time of urine accumulation in the bladder. Autonomic dysfunction in diabetes may 
also lead to a mixture of recently formed and stagnant urine.
6) A negative urine test cannot distinguish between hypoglycaemia, normoglycaemia and 
moderate hyperglycaemia (i.e. up to 10 mmol/1).
7) Urine testing is less accurate than with a blood glucose meter.
8) Some drugs may interfere with urine testing.
Many tests have shown that urine testing is a poor method of assessing glycaenuc 
control, giving only the crudest notion of the level of control (39,40). Urine testing is still 
recommended for those who are unable or unwilling to perform blood glucose testing (38), 
on the basis that some testing is better than no testing. For more stable NTDDM patients 
treated by diet or oral agents, urine glucose testing, when supplemented by regular 
glycohaemoglobin measurements, and perhaps fasting blood glucose tests, remains a 
reasonable means of monitoring control.
1.4.1.2 Urine Ketone Test
Urine ketones provide an indication of insulin deficiency and warn against 
impending or reflect established ketoacidosis (38). Commercial ketone tests are based on 
nitroprusside, which produces a purple colour with acetoacetate (e.g. Ketostix, Bayer 
Diagnostics), and also with acetone if glycine is also present in the reagent (e.g. Acetest 
tablets, Bayer Diagnostics). None of the nitroprusside based tests detect 3 hydroxybutyrato 
which is quantitatively the most important ketone body.
False-positive tests with nitroprusside reagents are reported to occur with sulphydryl 
drugs such as Captopril and exposure to air produces false negatives (41). It is 
recommended that urinary ketone testing is done during acute illness, during pregnancy and
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when symptoms of ketoacidosis are present (e.g. nausea, vomiting, abdominal pain). Blood 
3-hydroxybutyrate levels are not routinely measured in clinical practice.
1.4.2 Blood Glucose Testing
1.4.2.1 Single Measurement of Blood Glucose Concentration
In IDDM, blood glucose levels fluctuate widely throughout the day and are 
generally unpredictable from day-to-day. Fasting or random blood glucose measurements 
therefore give little or no indication of the overall level of glycaemic control, even on the 
day in which the sample is taken. Because of this, there is a poor relationship (r = 0.24) 
between random and postprandial blood glucose tests and glycohaemoglobin levels in 
IDDM (42,43), confirming that these samples give little information about overall control in 
the preceding few weeks. Nevertheless, random and fasting blood glucose measurements 
are traditionally performed on IDDM patients in most diabetic clinics but serve not much 
more than to alert the physician to hypoglycaemia, which must be corrected before 
consultation can begin.
In NÏDDM patients, blood glucose levels are more stable from day to day and have 
a similar pattern to that in non-diabetic subjects, though at a higher level and with larger 
postprandial peaks (44). There is thus a very good correlation (r = 0.68) between fasting 
plasma glucose and the mean daily plasma glucose levels and glycohaemoglobin percentage 
in NIDDM (43), so that a single clinic blood glucose value, particularly when fasting, 
provides a good estimate of overall control in NIDDM (44).
1.4.2.2 Blood Glucose Profiles
The best assessment of the variation in blood glucose concentrations throughout the 
day is provided by serially timed measurements either in hospital or at home. Self 
monitoring of capillary blood glucose by patients at home has become an integral part of 
modem intensified treatment of IDDM patients (45).
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Although it is desirable that all patients receiving insulin perform routine blood 
glucose self-monitoring (46), only about 40% of IDDM and 30% of NIDDM patients in the 
USA do so (47). Amongst the hindrances to thé increased use of self-monitoring are the 
discomfort of fingerprick blood sampling, the inconvenience of testing in terms of time and 
complexity, the high cost in some countries where there is no, or only partial, 
reimbursement of health service provision of supplies, and poor education of patients and 
health care professionals about the benefits. Improved methods of patient monitoring 
including non-invasive techniques are a priority.
Some benefits of blood glucose self-monitoring are:-
1) More accurate and patient-acceptable than the urine tests for glucose; i) on a day-to-day 
basis by the patient, ii) in the long-term by the physician
2) Defines the level of glycaemic control achieved; i) for research, ii) for routine clinical 
assessment
3) Identifies hypoglycaemia; i) impossible with urine testing, ii) particularly valuable in 
patients with loss of hypoglycaemia awareness
4) Acts as an educational aid
5) Increases patient participation, motivation and interest
6) Reinforces the patients feeling of 'being in control', thus offering independence and self- 
confidence
7) Improves quality of life
8) Reduces hospital admission
1.4.3 Glycohaemoglobin
Nomenclature : In 1978 the term glycosylated haemoglobin was introduced to refer
to the product of the non-enzymatic reaction between glucose and the free amino acid
groups of haemoglobin (48). In 1983 Roth, on behalf of the International Union of Pure and
Applied Chemists - International Union of Biochemists (IUPAC-IUB) Joint Commission on
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Biochemical Nomenclature (JCBN) pointed out in his journal (49) that the JCBN suggested 
that the term glycated haemoglobin for such amino-linked-1 -deoxyfructose derivatives of 
haemoglobin. In 1986 the JCBN finally recommended the term glycohaemoglobin (50). 
Because glycohaemoglobin is the officially recommended nomenclature, I shall be using this 
term in this project. Table 5 summarises glycohaemoglobin nomenclature.
Table 5 Summarises GHb nomenclature, based on the recommendations by the National 
Institutes of Health, Diabetes Data Group ( adapted from reference 51)
Table 5. Haemoglobin Nomenclature (51)
HbA The major form of haemoglobin, a native, unmodified tetramer consisting of two alpha
and two beta chains.
jjb a The major component of HbA, identified by its chromatographic and electrophoretic
properties. Posttranslational modifications, including glucosylation, do exist in this 
fraction but do not significantly affect the charge properties of the protein.
HbA1 Posttranslationally modified, more negatively charged forms of HbA, as detected by
(sometimes chromatographic and electrophoretic methods,
known as
"Fast" " .
Haemoglobin) The total HbA1 fraction, which because of a more negative charge, migrates more rapidly
toward the anode in electrophoresis and elutes earlier in cation-exchange chromatography 
than does HbAfl. The chromatographically distinct components of HbA  ^are>
HbAla l (fructose 1,6, ctiphosphate-N-terminal valine)
HbAiai (glucose-6-phosphate-N-terminal valine)
HbAlb (unknown carbohydrate-N-terminal valine)
HbAlc (glucose-N-terminal valine)
HbAlc Adduct of glucose attached to the beta chain terminal valine residue by a ketoamine
linkage.
Pre-HbAlc A labile form of glucosylated haemoglobin containing glucose attached by aldimine
or SchifF base linkage at the beta chain terminal valine residue.
Glucosylated Haemoglobin modified by glucose at alpha and beta chain terminal valine residues and
Haemoglobin(s) epsilon amino groups of lysine residues.
Total glyco- HbAlc + glucose -non-N-terminal lysine sites.
haemoglobin
(total GHb)
IlbAj is a series of glycated variants where various carbohydrates arc attached to 
the N-terminal valine of the beta chain of haemoglobin - either fructose 1,6-diphosphate
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(HbAla l), glucose-6-phosphate (HbAla2), or glucose (HbAlc) or an unknown sugar 
(HbAlb). The largest component (60-80%) is HbAlc and is frequently measured on its 
own. This glycation causes an increase in negative charge so that HbAj components are 
sometimes called fast haemoglobins because they run fast in electrophoresis systems. Total 
glycohaemoglobin (GHb) represents glucose attained to both the N-terminus (HbAjc) and 
to other sites such as the epsilon-amino group of lysine, which do not alter the charge. The 
reference range for HbA is about 4-6% and that for HbA ^  and total GHb higher at about 
5-7.5%, but the normal ranges must be established by each laboratory and cannot be 
interchanged (48).
Glucose reacts spontaneously and non-enzymatically with free amino groups on 
proteins to form covalent glycated proteins. The extent of protein glycation depends on the 
average glucose concentration to which the protein is exposed and on the half-life of the 
protein. Thus, long-lived structural proteins (e.g. lens proteins) may be damaged as a result 
of the abnormal increase in protein glycation found in diabetics. Indeed, it has been 
suggested that glycation of structural proteins in arterial walls and elsewhere might be 
responsible for some of the long-term sequelae of diabetes. Shorter half-life proteins such 
as haemoglobin may also undergo excessive glycation in diabetics (48).
The mode of reaction of glucose with proteins is shown in Figure 1. The carbonyl 
group of acyclic glucose reacts with the free amino groups via nucleophilic addition, 
forming a Schiffbase or aldimine. The labile Schiffbase may be hydrolysed back to glucose 
and protein, or it may undergo an Amadori rearrangement to form a relatively stable 
ketoamine linkage. The open chain of the amino sugar, 1 -amino-1 -de-oxyfructose 
(fructosamine), undergoes cyclization to a ring structure, mainly the pyranoside form. As 
this ketoamine linkage is fairly stable under physiological conditions and since there is 
no degrading enzyme(s) known in the mammalian tissue, once bound glucose stays with the 
protein throughout its lifespan (52).
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Fig. 1 The glycation reaction (52).
Since the half-life of Hb is about 60 days, the HbA j value reflects the average level 
of blood glucose concentration over the previous 1-2 months. As a consequence, levels of 
HbAj tend to be higher in diabetics. The extent of elevation indicates the overall average 
degree of blood glucose control; in poorly controlled diabetics, it may rise as much as 25%. 
In type I diabetics, the percentage of total Hb present as HbAj provides doctors with a 
better out-patient index of diabetic control than blood or plasma glucose concentrations, 
since it is little affected by short-term fluctuations in blood glucose concentration (53).
In diabetic clinics, HbAj is mostly used to assess control of insulin-dependent
diabetics and to complement home-monitoring of blood glucose. Studies have shown that
the HbAj value correlates well with the mean blood glucose over the preceding 1-2 months
and with clinical impressions of each patient's state of health. It provides an objective
measurement of glycaemic control and can be used to define a treatment goal for both the
patient and physician. Results of HbAj measurements have an important place in studying
the relationship between diabetic control and the longer-term development of diabetic
complications, and are valuable in the assessment of new treatment regimes. As a parameter
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of diabetic control, glycohaemoglobin is measured in addition to the urinary and blood 
glucose.
It is unlikely that HbAj measurements will ever displace home- monitoring of blood 
glucose as the mainstay of day-to-day control of diabetes by patients themselves, their 
friends or relatives. Technically, HbAj measurements are more time-consuming and much 
more expensive than glucose measurements (53).
There are circumstances in which glycohaemoglobin measurements are very useful:-
1) They are of special value in the routine management of insulin-dependent diabetic 
children in poor metabolic control. Here, frequent determinations are necessary since in 
these patients the glucose profiles are prone to great variations, which may lead to changes 
in the glycohaemoglobin concentrations. In adults, the frequency of glycohaemoglobin 
measurements must depend on the stability of the diabetic control obtained; twice a year in 
stable diabetics and four to six times a year in unstable diabetics (54).
2) In home monitoring of blood glucose, glycohaemoglobin determination has gained 
acceptance as the best parameter to detect objectively the effect of this kind of therapy and 
to measure patient complience. In particular, patients unsuitable for this kind of therapy are 
detected by frequent glycohaemoglobin measurement (54).
In the past clinicians have had to rely on historical information given by patients
home urine or blood tests and clinic blood glucose measurements. All these may be
unreliable or unrepresentative. Many patients feel perfectly well with relatively high blood
glucose concentrations and the classical symptoms of polyuria and thirst may not occur until
blood glucose concentrations are very high. The results of home monitoring may be
incorrect either because patients are not proficient in carrying out the test or because they
set out to mislead their doctors. Clinic blood glucose measurements provide no measure of
control at other times. They may also not be representative because the patient behaves
differently when a clinic visit is imminent or has an intercurrent illness which produces a
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higher result than normal. The advent of glycohaemoglobin determinations has 
demonstrated the limitations of the traditional procedures for assessing diabetic control (55)
3) In monitoring diabetic pregnancy - strict conrol of pregnant subjects is necessary because 
of a high risk of foetal abnormality Leslie et al. (56) and Miller et al. (57) have 
demonstrated a positive relationship between high glycohaemoglobin levels during the first 
trimester of pregnancy and foetal anomalies. Their results revealed a significantly higher 
incidence of major congenital anomalies in the ofispring of women with elevated 
glycohaemoglobin values. This was confirmed by Hinen et al. (58) who found that poor 
control of maternal diabetes and high glycohaemoglobin levels were associated with 
increased risk of perinatal death. Most foetal malformations occur before eight weeks of 
gestation, so problems of morbitity and mortality can be minimised only if patients with 
diabetes are maintained as euglycaemic, preferably before and during pregnancy (59). As a 
single glycohaemoglobin determination cannot satisfactorily predict the degree of 
regulation, both glycohaemoglobin and blood glucose should be determined regularly and 
frequently throughout the pregnancy (60).
4) The measurement of glycohaemoglobin is of the utmost importance in detecting the 
relationship between the degree of metabolic control and the occurrence of diabetic 
complications - see section 1.5 It must therefore be measured in all groups of patients 
subjected to different therapeutic regimens to establish long-range determinations of the 
degree of diabetic control obtained.
1.4.4 Fructosamine and Glycated Albumin
Analogous to the glycation of haemoglobin, serum proteins, the bulk of which is 
albumin, react with glucose and other sugars to form an aldimine linkage, which undergoes 
an Amadori rearrangement to a ketoamine. The concentration of glycated protein can be 
used as a measure of long-term glycaemic control over approximately the life-time of the
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albumin molecule, i.e. about 2-3 weeks. This test is commonly known as the 'fructosamine' 
assay (61,62), although fructosamine is the generic name for the protein-ketoamine product, 
and should strictly refer to any glycated protein assay. Johnson et al. (63) were the first to 
introduce a simple colorimetric assay for fructosamine in 1982, based on the ability of 
fructosamines to act as a reducing agents in alkaline solutions, distinguishable from glucose
and other reducing agents.
In the original assay (63), serum is added to carbonate buffer pH 10.8 (subsequently 
changed to 10.35) containing nitroblue tétrazolium (NTB), which is reduced to a formazan 
dye that absorbs at 550 nm. The original standard was a synthetic ketoamine, 
deoxymorpholinofructose (DMF), and gave a reference range of about 2.1-2.8 mmol/1. The 
assay was rapidly adapted for automated analysers. Numerous interferences were reported 
including lipaemia, bilirubin, ascoibate, haemolysis, uric acid and uraemia (61,62). The 
result is dependent on albumin concentration and there are arguments for and against 
correcting fructosamine values to the serum albumin value. While Johnson et al. (64) report 
that it is not necessary to correct for serum albumin concentration, others (65,66) have 
suggested otherwise.
Changes in the half-life of albumin may occur in catabolic and anabolic states 
(cachexia, thyroid disease) and in dysproteinaemias (paraproteinaemia, 
hypergammaglobulinaemia). The half-life of albumin is inversely related to its serum 
concentration. Results of fructosamine may also be invalid in the presence of cirrhosis of the 
liver, nephrotic syndrome, or after rapid changes in acute-phase reactants (67).
Recent improvements in the assay (68) include using a secondary standard of 
glycated albumin and incorporation of detergent into the reagent mixture to increase 
linearity and to eliminate protein-matrix effects and interference due to lipaemia. Added 
uricase eliminates interference from uric acid. The modified formulation and standard are 
commercially available (Boehringer Mannheim) and suitable for automated analysers.
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Affinity chromatography and immunoassays can be used for the assay of both glycated total
serum protein and albumin (69,70).
Fructosamine values correlate well with GHb in stable diabetes but less well when 
control has altered markedly in the past week or so (68). Because the test has good 
precision, low cost and is easily automated, it has been suggested as an alternative to GHb 
for monitoring control in diabetes. In situations where information is required about control 
over a shorter period than that measured by GHb, such as during diabetic pregnancy, 
fructosamine may be the method of choice (71). Other authors report that the correlation 
between the two tests is weak, reflecting the greater inter-individual variation in plasma 
proteins than in haemoglobin (66). Fructosamine assays are reported to be less reliable 
and GHb measurements are often preferred (66).
1.4.5 Other Glycated Plasma Proteins
Glycation of fibrinogen has been measured by affinity chromatography and reflects 
mean blood glucose over 2-3 days (72). Other products are discussed in section 1.5 and 
have been reviewed by Furth (73).
1.4.6 Glycation by Fructose
Fructose, a major dietary sugar, is a potent glycating agent forming advanced 
glycation end products (AGE) much faster than glucose. Although it reacts with lens 
protein and haemoglobin its study has been much neglected (74). The common assays for 
measuring glycation are unsuitable for measuring fructation and until a suitable, 
relatively simple assay is developed, its usefulness will go largely unexplored (75).
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1.5 The Long-term Effects of Extensive Glycation in Diabetics
1.5.1 Potential Mechanisms in the Pathogenesis of Complications
Pathogenesis of the various diabetic complications may not be uniform. Distinct 
abnormalities might operate in nerve and kidney, for example, or several abnormalities 
might act in concert. Three possible mechanisms have received considerable attention:
1) the glycation of proteins; 2) the polyol pathway, and; 3) the haemodynamic hypothesis
1 ) Can Extensive Glvcation of Proteins Produce Disease?.
The level of glycation of a protein in vivo is determined in part by its time of contact 
with a given level of hyperglycaemia. In addition, the turnover rate of the protein influences 
the extent of glycation. Proteins in plasma that turn over slowly, such as red-blood cell 
membranes (76), haemoglobin (77), albumin (78), low-density lipoproteins (LDLs) (79), 
high-density lipoproteins (HDLs) (80), and immunoglobulin G (81) become significantly 
glycated in diabetes. Outside the circulation, increased glycation has been found in lens (82), 
glomerular basement membrane, aorta, coronary arteries, and femoral nerve (83,84).
Interference with function of a protein by glycation requires either that the affected 
intrachain lysines be close to the active site(s) of the molecule or that stereochemical 
conformation of the protein be distorted. The function of some proteins is known to be 
altered by glycation, and in other cases the possibility is suspected but unproven. In the 
former category are haemoglobin, albumin, lens protein, fibrin, collagen, lipoproteins, the 
glycoprotein recognition system of hepatic endothelial cells (85), and antithrombin m  (86). 
In the latter category are immunoglobulin G, red-blood cell membranes, circulating white-
blood cells, myelin, and Von Willebrand factor.
Glycation of haemoglobin blocks the reaction of 2,3-diphosphoglycerate with
positively charged residues on the beta chain, causing a slight but clinically significant
increase in oxygen affinity. Glycated albumin inhibits the hepatic uptake of glycoproteins
and is taken up into small blood vessels more rapidly than native albumin, but a report that
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it binds to glomerular basement membranes (87) has not been confirmed (88). Glycated 
fibrin is less susceptible to digestion by plasmin (89), which might account for its extensive 
accumulation in diabetic tissues (90). Non-enzymatic glycation of the crystalline proteins of 
the lens may promote the formation of disulphide links between protein molecules (82); 
aggregates of crystalline protein with molecular weights in excess of 5 x 10 ^ scatter light,
i.e., they constitute a cataract.
It is not known whether glycation of collagen in glomerular basement membranes is 
related to their thickening in diabetes. There appears to be a generalised increase in 
basement membrane thickness (91). Glycated collagen is more insoluble and resistant to 
digestion because of increased intramolecular cross-lmkmg (92), which may decrease its 
degradation. It has also been postulated that decreased proteoglycan synthesis causes 
increased permeability of basement membranes and the thickening is a compensatory 
response (93).
It has been reported that glycated collagen is antigenic in rats and that rats with 
streptozocin-induced diabetes form antibodies to glycation but not native collagen (94). If 
this is true, antibodies to glycated collagen could damage the glomerular basement 
membranes either directly or via immune complexes. Conceivably, the absence of severe 
microangiopathy in some poorly controlled diabetics could represent a reduced 
immunological response to glycated collagen.
Glycated skin collagen is resistant to digestion by collagenase (95). It is not clear 
whether glycation is responsible for connective tissue changes, such as tight waxy skin and 
limited joint mobility, that are said to indicate an increased risk of late complications (96).
Glycation of the red cell membrane could play a role in the 15% reduction in
erythrocyte survival time (97) and perhaps in the loss of the normal red-blood cell
deformability that occurs in poorly controlled diabetes (98). Normal red-blood cells pass
easily through capillaries with luminal diameters smaller than their own because they are
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deformable; loss of flexibility could cause sludging of blood and contribute to retinal and 
renal ischaemia (98). Glycation of myelin protein (99) may account in part for the
functional changes in nerve conduction.
Theoretically, extensive glycation of insulin receptors could contribute to the 
reduced sensitivity to insulin that occurs in chronic hyperglycaemia (100) and is reversed by 
meticulous control (101). Membrane glycation in leukocytes conceivably might account for 
the reduced chemotaxis (102), phagocytosis, bacterial activity (103) and cell-mediated 
immunity (104) reported in diabetes, although this has not yet been explored. The defective 
response of T cells and B cells to mitogens can be restored by the normalisation of glucose 
(105). Extensive glycation of Von Willebrand factor could contribute to the increased 
platelet aggregation reported in poorly controlled diabetes (106). Advanced glycation end 
products have been proposed as a major factor in diabetic macrovascular disease (107). By 
cross-linking matrix and plasma proteins, they may accelerate development of 
atherosclerosis.
2) The Polyol Pathway
A second general mechanism possibly underlying diabetic complications is activation 
of the polyol pathway (108). In this pathway glucose is reduced to sorbitol under the 
influence of the enzyme aldose reductase (D-aldose: NADP+ 1-oxidoreductase) with 
NADPH as cofactor. Sorbitol can then be oxidised to fructose with the production of 
NADH by the enzyme sorbitol dehydrogenase (L-iditol dehyrogenase). Aldose reductase is 
present in the retina, kidney papillae, lens, Schwann cells, and aorta, tissues that are 
frequently damaged in diabetes. Polyols have been implicated in the pathogenesis of 
cataracts (109), retinopathy (110), neuropathy (111) and aortic disease (112). In the lens, 
sorbitol, may cause osmotic swelling, which is initially reversible, but subsequently, Na+, 
K+-ATPase activity falls (109). How the latter interacts with the postulated role of
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glycated lens proteins in the genesis of cataracts (82) is not known. In nerves polyols also 
inhibit Na+, K+-ATPase (113,114) a lesion that accompanies the characteristic myo­
inositol deficiency found in experimental diabetic neuropathy (111). Although myo-inositol 
deficiency is routinely observed in nerves from diabetic rats and repaired by myo-inisitol 
feeding (115), biopsy specimens of sural nerve from humans with diabetic neuropathy failed 
to show diminished levels of myo-inisitol (115). Further studies will be required to 
understand the discrepancy. Experimentally, retinopathy (110), cataracts (109), 
nephropathy (108), and the metabolic abnormalities of peripheral nerve (111,114) can be 
prevented by inhibition of the polyol pathway. Sorbinil, an aldose reductase inhibitor tested 
in human trials, may relieve symptoms in painful diabetic neuropathy (116) and in long-term 
treatment appears to enhance nerve regeneration in diabetic humans (117). The use of these 
inhibitors as prophylaxis for complications has not been reported.
Non-enzymatic glycation of proteins and the polyol pathway may not be unrelated 
mechanisms. It is now known that fructose generated in the polyol sequence can non- 
enzymatically bind to protein (called fructation) and that fluorescence of collagen from 
diabetic animals is decreased by inhibitors of aldol reductase (118). It is thus possible that 
an active polyol pathway may contribute significantly to non-enzymatic glycation of 
proteins.
3) Haemodynamic Hypothesis
A third postulated general mechanism of tissue injury is based on the observation
that blood flow is increased in patients studied shortly after the onset of IDDM (119).
Because blood pressure is usually normal in such patients, it is likely that arteriolar
resistance is decreased. The increased hydrostatic pressure in the capillary beds is thought
to increase filtration of potentially damaging proteins and other macromolecules (including
immune complexes) into the walls of blood vessels and mesangium, secondarily stimulating
synthesis of mesangial and basement membrane components. The latter step is presumed to
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enhance capillary leakiness', setting up a vicious circle. The haemodynamic hypothesis has 
received most attention in connection with diabetic renal disease (120). In view of the wide 
spectrum of dysfunction that characterises the diabetic state, the probability that a single 
abnormality like hyperfusion, by itself, could cause microangiopathy is low.
1.6 Methodology for Glycohaemoglobin Measurement
The major assay methods can be divided into categories, based on the manner in 
which glycated and non-glycated haemoglobin components are separated. Each is discussed 
in detail.
1.6.1 Methods Based on Charge Differences
1.6.1.1 Cation-exchange Chromatography
This is the most widely used method in clinical laboratories around the world. 
Procedures range from disposable microcolumns to expensive "high-performance" 
automated systems. The principle of the method is that many GHb species, including 
HbAjc, are less positively charged at neutral pH than HbAg, and bind less well to a 
negatively charged resin. Typically, the haemolysate is applied to a column filled with resin 
and the eluate is collected. The less-positively charged minor haemoglobin components, 
primarily HbAla, Alb, and Alc, elute before the main haemoglobin fraction, HbAq, and 
their percentages of total haemoglobin can be easily determined with a spectrophotometer. 
Some procedures only separate HbAj (HbAja+b+c) from HbA^; others separate the 
various minor haemoglobin components from one another, thereby allowing quantification 
of HbAlc (121).
Numerous commercial cation-exchange chromatography kits have been marketed 
for the measurement of glycohaemoglobin (122,123). Most involve haemolysis of 
anticoagulated whole blood, application of the haemolysate to a pre-filled disposable
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column of cation-exchange resin, and finally, elution of HbAj with one buffer and of HbAg 
with a second buffer. Many variations of this technique have been reported, including a 
resin slurry method (124), and a rapid column-centrifugation method (125). A few cation- 
exchange methods have been described that separate the HbAjc from HbAj^+y (126-128). 
Typically, these methods also involve two buffers: the first to elute the HbA^+y fraction, 
and the second to elute HbAjc. HbAg is not eluted from the column, but is quantified 
indirectly by determining the absorbance of the haemolysate before application to the 
column.
Several high performance liquid chromatography (HPLC) systems have been 
marketed for the measurement of glycohaemoglobin by cation-exchange chromatography. 
The increasing numbers of glycohaemoglobin requests received by laboratories has resulted 
in the need for increased automation, turn-around time, and high sample throughput. 
Dedicated HPLC systems have become commercially available for the estimation of 
HbAj/HbA|c, although non-dedicated systems adapted to the analysis of 
glycohaemoglobin, are becoming more widely available. There is currently available one low 
pressure, and several high pressure cation exchange resin systems.
Law pressure system:- The GHycomat analyser and its successor the Hb Gold are 
manufactured by Drew Scientific, and distributed in the U.K. by Ciba Coming Diagnostics, 
and Biomen Ltd., respectively. This system uses two buffers and mini-columns, each 
capable of performing at least 150 separations before it has to be changed. The instrument 
will give results as HbAj, HbAjc, and may be adjusted for the estimation of HbF 
and HbS (129).
High pressure system:- There are several systems available:
a) The Diamat Analyser (used in the Diabetes Control and Complications trial) and its 
successor the variant Analyser are manufactured by Toya-Soda, Tokyo, Japan; distributed 
by Bio-Rad laboratories, Hemel Hempsted, U.K. These require sample pre-treatment before
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loading onto the autosampler. The analyser utilises a tertiary gradient and produces HbAj 
and HbAlc results. The results are not obtained directly from the peak areas, but are 
calculated from comparison with calibrant chromatograms stored in the instrument; this is 
necessary to correct for peak broadening as the column ages.
With a different column and eluants the instrument can be used to quantify and 
detect a wide range of abnormal haemoglobins HbS, C, F, and E with the glycohaemoglobin 
protocol (130).
b) The Shimadzu HPLC haemoglobin System (Dyson instruments) also corrects the results 
obtained after comparison with calibration chromatograms; but unlike the Diamat system 
uses a binary elution gradient (130).
The greatest degree of automation is shown by the
c) Daiichi Hi-Auto Alc HA 8121 manufactured by Kyoto Daiichi, Kagoto, Japan; 
distributed by Biomen Limited, Croyden, U.K. It is at present unique in its ability to 
dilute, haemolyse and remove the labile fraction of HbAjc within the instrument. This is 
achieved by incubation of the sample in a thermal-jacketed loop for 2 minutes at 48°C in 
the presence of tetrapolyphosphate at pH 6. This instrument is dedicated to the 
measurement of HbAj and HbAjc (130).
In general, HPLC methods show excellent assay precision, and permit rapid 
separation of HbAj c from other minor haemoglobin components and HbAg. Haemolysate is 
injected onto a small glass column filled with cation-exchange resin. For most, HPLC 
methods, a two-buffer system is used, similar to the disposable column methods. The first 
buffer, which has a higher pH and lower sodium ion concentration than the second, is 
pumped through the column under moderate pressure and at a rapid flow rate. After elution 
of the various minor haemoglobin fractions, the second buffer is pumped through the 
column to elute HbAg. The absorbance of the eluate is monitored continuously, allowing 
quantification of each minor haemoglobin component. This method can be fully automated.
32
Despite its advantages, however, HPLC requires meticulous laboratory technique for 
achieving and maintaining optimal results. Equipment costs are high, but for laboratories 
that analyse many specimens per week, the cost per test is comparable with that of 
disposable microcolumn methods. As none of these analysers are capable of resolving the 
HbAlc peak from neighbouring peaks, experienced chromatographers question their 
accuracy.
1.6.1.2 Electrophoresis
1) Agar Gel Electroendosmosis
In 1980 Menard and co-workers (131) described a method using agar 
electroendosmosis. Haemoglobin Aq, being more positively charged than HbAj, interacts 
more strongly with the fixed negative charge of the gel matrix, while the HbAj is swept 
towards the cathode by the electroendosmotic flow of buffer. A commercial kit (Coming 
Medical, Halstead, Essex. U.K.) incorporating electroendosmosis methodology compared 
favourably with a short column chromatographic method. Unlike ion-exchange 
chromatography, electroendosmosis was not significantly affected by fluctuations in 
temperature (132).
Puukka et al.(133) have shown that HbAj as measured by the electrophoretic
method is acutely responsive to changes in glucose concentrations. The contribution of the
labile fraction is eliminated by saline incubation of the erythrocytes or dialysis of the
haemolysates before the assay. The removal of the unstable component before analysis of
the electrophoretic method will minimise the effect of any acute changes in the blood
glucose concentration on the level of HbAj and thus make it a more accurate indicator of
long term glucose control in diabetic patients, but will complicate an otherwise simple and
rapid procedure (133). Increased percentages of HbF are also known to interefere with
glycohaemoglobin measured by electrophoresis based on the electroendosmotic separation,
and carbamylated haemoglobin has been shown to interefere with methods based on charge
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separation (132).
2) Agarose Electrophoresis
Recent years have seen improvements in electrophoretic methods. Agar systems 
have been replaced by agarose gels (Diatrac; Beckman) and electrophoretic methods have 
been automated (REP automated electrophoresis instrument; Helena Laboratories, 
Gateshead, UK). The Helena rapid electrophoresis (REP) system was the first automated 
electrophoresis instrument available commercially and can be used for a variety of clinical 
and research electrophoresis applications. The REP method is capable of quantitating 
abnormal haemoglobins e.g. HbS. Further work is under way to determine if a modified 
formulation of the gel can improve the resolution sufficiently to separate HbC (134).
1.6.1.3 Iso-electric Focusing
The greater specificity of HbAlc by iso-electric focusing makes an attractive 
alternative to chromatography, but some observers have commented that 'the separation is 
not, however, adequate for quantitation or isolation of HbAjc, and that the ‘technical 
difficulties involved in this method do not permit its routine clinical application' (135). 
Iso-electric focusing in polyacrylamide gels is a special type of electrophoresis that 
separates haemoglobins according to their iso-electric points (Pis) (136). The haemolysate 
is subjected to an electrical current in a gel that has been specially prepared to have a pH 
gradient. The pH gradient is established by means of specialised carrier ampholyte mixtures 
of polyamino and polycaiboxylic acids with differing Pis. Each haemoglobin component 
"focuses" as a single band in a gel at its specific PI. HbA|c focuses well separated from 
HbAg and the other minor haemoglobin components. Haemoglobinopathies do not affect 
results, but pre-Alc does interfere. The necessary equipment is expensive and results 
correlate well with other methods for quantifying GHb, and the assay precision is
comparable with that of other methods (136).
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1.6.1.4 Factors Affecting Charged-based Methods
The various factors that affect the results of cation-exchange chromatography can 
be divided into two categories: those that are related to characteristics of the measurement 
technique (assay factors), and those that are related to some characteristic of the blood 
sample.
1) Assay conditions. Assay conditions that can affect test results include temperature, pH, 
ionic strength, column size and flow-rate (137,138). Failure to appreciate these important 
factors accounted for much of the variability in test results encountered shortly after the 
introduction of cation-exchange chromatographic procedures.
2) Labile interm ediates. Shortly after the introduction of microcolumn techniques for 
measuring GHb, several studies suggested that formation of GHb was both rapid and 
reversible, raising important questions concerning the validity of GHb measurements as 
indicators of long-term glucose control (139-141). We now know that formation of GHb is 
a two stage process, with initial formation of an intermediate Schiffbase from glucose and 
haemoglobin A. This labile component, called pre-Alc when glucose is attached to the 
NH2-terminal valine of the beta chain, then either undergoes an irreversible molecular 
arrangement to form GHb (a ketoamine), or dissociate back to glucose and haemoglobin A 
(48). Unfortunately, the intermediate, which is acutely responsive to glucose 
concentrations, co-chromatographs with GHb and will falsely increase test results for 
HbAlc. Thus, it is necessary to remove the intermediate before assay; otherwise, results will 
reflect a combination of short- and long-term glucose control. Among the methods available 
for removal of this labile component are incubating erythrocytes in saline solution and lysing 
blood samples in low-pH buffer (142,143). Fortunately, most manufacturers of cation- 
exchange microcolumns routinely include such lysing agents in their kits.
3) Haemolytic anaemia's, phlebotomy, and pregnancy. These situations all tend to 
decrease GHb results from expected values in proportion to the degree that erythrocyte
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survival time is shortened (144,145).
4) Haemoglobinopathies. Several haemoglobin variants are associated with either falsely 
increased or falsely decreased GHb values, depending on the charge characteristics of the 
particular variant (146).
Blood from adults contains up to 0.5% of foetal haemoglobin (HbF). The HbF 
fraction is often significantly elevated in patients suffering from thalassaemias, in those with 
structural varients of haemoglobin (146), and rarely as a result of hereditary persistence of 
foetal haemoglobin (147). It is raised to a lesser extent in pregnancy and in a variety of 
other conditions. Levels of HbF have also been shown to be higher in a proportion of 
children and adolescents with type I diabetes than in controls and are often in excess of 
0.5% (148). HbF is negatively charged and co-chromatographs with "fast haemoglobins" 
and will increase the apparent concentrations of HbAj c or HbAj quantitated by some ion- 
exchange methods (149). The Diamat, HA8121 and the Shimadzu systems all achieve 
acceptable resolution of HbAjc from HbF, but with the glycomat, HbAjc and HbF co-elute 
(130).
Positively charged haemoglobins e.g. sickle cell haemoglobin (HbS) may be retained 
by some column methods resulting in low haemoglobin fractions (146). In HbS, the 
charged glutamic acid residue in position six of the normal beta chain is replaced by an 
uncharged valine molecule.
The gene for HbS occurs especially in a wide area across Tropical Africa, in some
parts of the countries bordering on the Northern shores of the Mediterranean, and in parts
of the Middle East and Southern India. The prevalence of this gene in these areas varies
from very low values to 40% of the population. In black Americans, the prevalence is 8%.
The distribution of the HbS gene corresponds to areas in which falciparum malaria has been
endemic and the persistence of this potentially lethal gene in high frequency in these areas
results from the fact that heterozygotes die less frequently from severe falciparum malaria
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during early childhood than children with only HbA (150).
The automated liquid chromatography systems (Diamat and Glycomat) identify Hb 
traits but not their glycated fractions. With the Shimadzu and Daiichi HAS 121 abnormal 
haemoglobins are eluted with or shortly after HbAg, and the only indication of an 
abnormality will be, in most cases, an unexpectedly low HbA^c (as a percentage of apparent 
HbAfl). The clinical implications of this is that a diabetic with a known haemoglobinopathy 
may well give a falsely low (apparently normal) glycohaemoglobin result in the presence of 
poor control. In most diabetic populations, these haemoglobin variants are relatively 
uncommon, but in clinical situations where these variants are found frequently, methods that 
are not based on charge differences might be preferable to cation-exchange chromatography 
(130).
5) Interfering substances. When haemolysates are prepared directly from whole blood, 
markedly above-normal concentrations of either triglycerides or bilirubin will falsely 
increase results for HbA^ and H b A (137,151). Bilirubin migrates with the fast 
haemoglobin' and absorbs at the detecting wavelength. Lactescent plasma due to 
hyperlipidaemia can also cause elevation of HbAj, since lactescence elutes in the first HbAj 
fraction and absorbs at 415 nm.
6)Non-glucose adducts o f haemoglobin. Various substances other than sugars can form
adducts with haemoglobin, thereby altering its charge characteristics. Unfortunately, in
some cases, these adducts co-chromatograph with the minor haemoglobins, falsely
increasing test results. Examples include individuals with opiate addiction (152), lead
poisoning, uraemia, and alcoholism, as well as those receiving chronic treatment with large
doses of aspirin. Aspirin modifies several sites, presumably lysines, on both the alpha and
beta chains of HbA. Acétylation of lysine residues with aspirin confers a negative charge on
the modified protein. The modified haemoglobin has altered electrophoretic and
chromatographic (ion-exchange) properties, migrating ahead of HbAg like HbAj. Patients
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with long-term high-dose aspirin therapy may have two-fold increase in the modified 
haemoglobin (153).
Clinically, the most important of these interfering adducts occurs in uraemia. 
Fluckiger and co-workers, using a gas-liquid chromatography method, first demonstrated 
elevated levels of carbamylated haemoglobin in uraemic patients and showed that the 
elevated levels correlated well with the time-averaged urea concentrations in haemodialysis 
patients (154). In renal Mure, significant numbers of patients have impaired glucose 
tolerance, and those on dialysis are usually dialysed against a fluid with a high glucose 
content. It is likely that some increase in HbAj will occur due to the presence of increased 
glucose concentration (although patients in chronic renal failure have a tendency to 
shortened red cell survival). However, it appears that most of the increase in uraemic 
patients is due to carbamylation of haemoglobin with cyanate or ammonia. Cyanate appears 
to react with protein amino groups, preferentially but not exclusively with alpha amino 
groups (154). Therefore, in uraemic patients HbAj results obtained using methods relying 
on charge separation must be interpreted with care. In most of the above situations, 
including uraemia, the HbAj^+y fraction is more affected than HbAj^. Thus, assays that 
quantify HbAlc specifically show only slight alterations (rarely greater than 1% GHb) from 
these interferences (149).
7) Sample handling and storage conditions. Numerous studies have been conducted on
the effect of blood storage on test results. Stored at temperatures above 4°C, the HbAj a+^
fraction shows steady increases that are time and temperature dependent (137,155,156).
HbAlc is only slightly affected. Thus, methods that determine HbAj will show falsely
increased values if specimens are not handled properly before assay. Whole blood
specimens are stable up to one week at 4°C, or for many months under ultra-cold storage
conditions (-70°C or colder). The clinician and laboratory personnel should co-ordinate
efforts to ensure proper sample handling and storage procedures, to minimise any analytical
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errors produced by inappropriate sample handling.
1.6.2 Immunoassay Methods
1.6.2.1 Enzyme Immunoassay
Novoclone HbAlc (Dako Diagnostics Ltd., Ely, U.K. - formerly known as Novo 
Nordisk) is an enzyme-linked immunosorbent assay (ELISA) kit based on a monoclonal 
antibody specific to the N-terminal end of the haemoglobin beta chain with glucose attached 
to it in its stable ketoamine form. Erythrocytes are washed, lysed and incubated for 10 
minutes at 15°C - 30°C.
The resulting haemolysates are mixed with coating buffer and loaded immediately 
into microtitre plate wells where the haemoglobin species bind directly to the polystyrene 
surface. Unbound material is removed by washing and antibody conjugated to horseradish 
peroxide is added. Further washing removes excess conjugate and HbAjc is estimated by 
measuring the remaining peroxidase activity after timed reaction with o-phenylenediamine 
using a microtitre plate reader. Results are expressed as percentage HbAlc from a standard 
curve derived from the four calibrants analysed in duplicate on each plate. Partial 
automation of the procedure is now possible using the Tecan 5032 sample processor and 
washing system (Tecan U.K. Ltd., Reading U.K.).
The antibody used in this method recognises the first four amino acids on the beta 
chain of the haemoglobin, and therefore will not recognise HbS (beta 6 glu— > val) or HbC 
(beta 6 glu— > lys) where the amino acid change is on position six (130).
1.6.2.2 Immunoturbidimetry
A HbAj g method based on the homogeneous immunoassay (Tina-Quant) has been
introduced by Boehringer Mannheim U.K. The assay is based on the photometric (570 nm)
determination of total haemoglobin and the immunoturbidimetric determination of HbAjc.
An antibody, recognising the first four amino acids and glucose on the beta chain of
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haemoglobin, reacts with HbAlc to give a soluble immune complex. Polyhaptens then bind 
to excess antibodies and the resulting agglutinated complexes are measured turbidimetncally 
at 340 ran. The agglutinated complex is inversely proportional to the analyte concentration 
in the sample. Due to the utilisation of high specificity antibodies, the method does not 
cross-react with HbAq, HbAla, HbAlb, acetylated haemoglobin, carbamylated 
haemoglobin or Schiff base. Additionally, as the antibody recognises the first four amino 
acids no interference should be seen with HbS or HbC.
A very similar immunoturbidometric method has recently been introduced by Roche 
Diagnostic Systems. This method includes pepsin in the lysing reagent, the proteolytic 
degradation making the beta-N-terminal structure more accessible for the HbAlc 
immunoassay. This method utilises an antibody which recognises the first three amino acids 
on the beta chain of the haemoglobin so, again, there should be no interference with HbS or 
HbC (130).
1.6.2 3 Immunoassay HbAlc Analyser (DCA 2000)
This analyser measures the concentration of HbA^c and the concentration of total 
haemoglobin; the ratio of the two is displayed as % HbAlc . The analyser utilises a cartridge 
which contains all the necessary reagents. Haemoglobin Alc is estimated using a method 
based on inhibition of latex agglutination. A synthetic polymer containing multiple copies of 
the immunoreactive portion of HbAlc causes agglutination of latex particles coated with 
HbAlc specific mouse monoclonal antibody. This analyser has been designed specifically 
for use in the clinic or doctor’s office laboratories. Finger prick samples are used. 
Specimens are analysed singly using a disposable cartridge and results are available in nine 
minutes (130).
High reagent costs and slow throughput make this analyser unsuitable for a hospital 
laboratory. In general the immunoassay methods are not as reproducible as the
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chromatographic methods.
1.6.3 Colorimetric Methods
The first determination of glycohaemoglobin HbAlc was described by Fluckiger and 
Winterhalter (157) and refined by Fischer et al. (158). In their TEA assay 5-hydroxymethyl 
furfural (5-HMF) was liberated from HbAlc by oxalic acid and subsequently complexed 
with thiobarbituric acid (TEA) to yield a coloured complex which could be measured at 443 
nm. A first evaluation of this technique was not successful. However, very good 
correlations with macro - or mini column methods have been described (135,159). Both 
Gabbay et al. (153) and Pecoraro et al. (159) have demonstrated that, in contrast to the 
chromatographic and electrophoretic techniques, the chemical assay detects glycosylation 
not only at the N-terminal amino group of the beta chains, but also the substantial glycation 
of the N-terminal amino groups of the alpha chain and of the epsilon amino groups of the 
lysine residues in both alpha and beta chains.
The TEA method can be automated very well and can be used for the determination 
of both glycohaemoglobins and glycated proteins (160). The various steps of the TEA 
method were evaluated (161,162), resulting in small changes in the original method. Only 
Dolholfer and Wieland (163) evaluated the assay critically. They stated that the TEA 
reaction yields erroneous results unless strictly standardised. Critical points are>
a) The amount of protein must be kept identical in all samples
b) Dialysis for removal of glucose and NaBH^ before hydrolysis is essential
c) The choice of acid, acid concentration, temperature and time of hydrolysis is critical
d) Appropriate NaBH^ concentrations must be used for the reaction
Comparing the result of determining the glycation of total protein and albumin, 90% 
of glycated serum protein is accounted for by glycated albumin. HbF is not measured by the 
TBA-reaction and carbamylated haemoglobin has been shown not to interefere with the
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specific thiobarbituric acid colorimetric method ( 163).
A completely different colorimetric method for the determination of 
glycohaemoglobins is based on the reaction of glycosyl residues with a phenol: sulfuric 
acid mixture (164) This reaction should yield a higher recovery of liberated glycosyl 
residues with an ever better correlation with the ion-exchange method than does the TEA 
method. Competition from the newer chromatographic methods have caused the 
colorimetric assays to decline in popularity.
1.6.4 Affinity Chromatography
Affinity separation of glycohaemoglobin was first discribed by Mallia and co- 
workers in 1981 (165). AfiBnity chromatography is a technique for separating large 
molecules on the basis of their chemical structure. The stationary phase, which is packed in 
a column, consists of an insoluble, inert matrix, such as agarose or cellulose, with an 
appropriate ligand attached. When the mobile phase containing the substances to be 
separated is passed through the column, the substances are separated by their different 
interactions with the ligand. The matrix is cross-linked agarose and the ligand is m- 
aminophenylboronic acid. Like the Amadori product of any protein, glycohaemoglobin 
contains c/s-diol groups in the sugar portion of the adduct (adjacent hydroxy groups in 
the cis configuration) which form five-membered ring complexes with boronic acid (165).
The boronate has high affinity for 1,2-cfj-diols, as in the stable ketoamine 
glycohaemoglobin complex, but not for the labile aldimines. The affinity column binds all 
ketoamine glycoproteins, including haemoglobins A jc, A ja, and A^y. It may also be used 
for quantitating glycosylated plasma albumin, for which the turnover is more rapid than that
of glycohaemoglobin.
Haemolysates may be prepared from whole blood or packed erythrocytes and
when absorbed on to the solid phase washed with two buffers. The first buffer elutes the
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non-glyeated fraction, which does not have trzj-diol groups and^  therefore* does not bind to 
the boronic acid. The bound fraction, which should contain only GHb, is eluted with the 
secon4 buffer which usually contains sorbitol, a sugar alcohol that displaces GHb from the 
column. Figure 2 shows the interaction between glycohaemoglobin and the m- 
aminophenylboronic add.
ŒbOH
Immobilised boronic acid Binding of glycohaemoglobin
to affinity matrix
Figure 2 Interaction between glycohaemoglobin and the /n-aminophenylboronic acid 
The following affinity chromatography procedures were used in this project
1.6.4.1 Pierce Affinity Chromatography
Pierce affinity chromatography (Pierce and Warriner, Cambridge, U.K.) Glycotest 
H columns are filled with agarose gel bearing /n-aminophenylboronate groups, which have 
affinity for c/s-diol groups. The glycohaemoglobin containing the c/s-diol groups are 
retained by the aminophenylboronate column while the non-glycohaemoglobin is eluted 
using a high concentration of the competing ligand, sorbitol. The absorbance of the 
separated glycohaemoglobin fractions are measured at 414 nm, and the percentage of
haemoglobin that is glycated is calculated (166). For the detailed methodology see 
section 3.6 (167).
Attempts at automating the Pierce method by incorporating a mini-column 
containing gel in a flow based system were disappointing. With use the gel compacted 
giving slow throughput and drifting results (168).
1.6.4.2 Drew Scientific GHb-100 Analyser
Drew Scientific GHb-100 analyser (Drew Scientific Ltd., Sowersbywoods 
Industrial Estate, Burrow-in-Fumess, Cumbria, U.K.). The GHb-100 analyser is a pre- 
production automated low pressure liquid affinity chromatography instrument for the assay 
of glyculiaenioglobin. The GHb-100 analyser is designed to carry out tests on whole blood 
with a minimum of sample preparation and is provided with a 100 position autosampler for 
unattended automatic operation. The ratio of the glycohaemoglobin to non- 
glycohaomoglobin can be estimated in the presence of variants and without interference
o
from foetal haemoglobin (HbF)
The GHb-100 analyser comprises of a pair of syringe pumps, three multiport rotary 
valves and a fixed wavelength flow-through spectrophotometer in conjunction with a 
computer control system to perform boronate affinity on haemoglobin samples. The rotary 
valves allow the syringe pumps to fill from the reagent bottles and then in reverse direction 
provide a flow of reagent to the chromatography column. Sample loading from the 
autosampler is achieved by using one of the rotary valves. The GHb-100 analyser uses low 
pressure liquid chromatography to separate glycohaemoglobin from non glycohaemoglobin, 
The separated haemoglobin fractions are monitored by means of light absorption at 415 nm. 
The chromatogram obtained is stored by the internal computer. A software program 
performs the analysis of the chromatogram and generates a result report on both the 
cathode ray tube display and on the printer. For detailed instructions see section 3.7 (169).
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1.6.4.3 Advantages of the Affinity Method
Glycohaemoglobin measurement by affinity chromatography has many advantages 
over other methods. Affinity chromatography is not affected by the Pre-HbA^ as the 
boronate has a high affinity for 1,2 c/'s-diols, as in the stable ketoamine glycohaemoglobin 
complex, but not for the labile aldimines. The affinity column binds all ketoamine 
glycoproteins, including haemoglobins A jc, A |a, and A possible explanation is that 
the Schiff base adducts are dissociated during chromatography and therefore do not have a 
strong interaction with m-aminophenylboronate. The affinity method, being totally 
insensitive to Schiff base, thus provides a more reliable measurement of stable GHb 
compared to the other methods, obviating the extra step of saline incubation (149).
With all methods, the importance of investigating unexpectedly low results and 
examination of individual chromatograms for unusual peaks cannot be overestimated. The 
best approach with patients with abnormal haemoglobins is to measure total GHb by affinity 
chromatography. Affinity chromatography is the only analytical system that is unaffected by 
the presence of abnormal haemoglobins. The affinity gel detects the glucose bound to 
haemoglobin, the type of haemoglobin (or indeed the type of protein) does not affect the 
separation. If there is complex mix of haemoglobin variants, then this assay must be the 
method of choice. The presence of carbamylated haemoglobin does not interfere with the 
specific phenylboronic gel affinity chromatography method, therefore this method can also 
be applied to renal patients with uraemia. (149).
Contrary to the statement of Mallia et al. (165), the affinity method has been 
reported to be susceptible to changes in pH and temperature (170); an increase in either was 
found to give a small increase of haemoglobin bound to the column. However, 
the affinity method was found to be considerably less sensitive to such changes than is the 
method using mini ion-exchange columns (170).
Ion-exchange and colorimetric results have both been shown to depend highly on
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sample size variation (137,149). The application of a greater than recommended 
haemolysate concentration to commercially available ion-exchange mini-columns can shift 
the elution profile sufficiently to cause anomalous results because of poorer separation 
between the slow and fast fractions. Haemolysate concentration is even more critical in 
TEA colorimetry, because the results are expressed as nanomoles of hydroxymethyl furfural 
per 10 mg of haemoglobin. Any variation from the assumed quantity of haemoglobin per 
test will affect results proportionately. The affinity interaction, however, appears to be 
relatively independent from such errors since the final glycohaemoglobin concentrations are 
expressed in proportional and not absolute terms. Therefore, the affinity method is 
applicable to almost the entire range of concentrations encountered in normals and in 
diabetic patients (149,170).
1.6.4.4 Drew versus Pierce
The users of the Drew Scientific GHb-100 analyser can easily be trained in the use 
and maintenance of the analyser, as it is very simple and easy to use. Therefore, highly 
skilled personel are not required to analyse the glycohaemoglobin samples. Once loaded the 
samples can be left while the laboratory worker carries out other analyses, or may be left 
overnight. No reagent preparation is necessary as Drew Scientific provide all the necessary 
reagents pre-prepared. The GHb-100 analyser does not require poisonous reagents such as 
oxalic acid and thiobarbituric acid which are required for the colorimetric methods of 
measuring glycohaemoglobin. Once the glycohaemoglobin samples have been haemolysed 
and mixed thoroughly, they may be loaded on the GHb-100 analyser and assayed 
immediately.
The Special Chemistry section of Clinical Pathology at the Royal Sussex County
hospital currently analyses approximately 900 patient samples per month for
glycohaemoglobin. Until recently, glycohaemoglobins were assayed by the manual Pierce
method, which is cheap in terms of consumables but is labour intensive. With the ever
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increasing workloads, the continued use of the manual technique resulted in a backlog, 
increasing turn-around times (in excess of 5 working days), and contributed to stress, 
particularly for medical laboratory assistants and junior biomedical scientists.
There are cost pressures associated with this change in technique, but it is not viable 
to continue with the manual Pierce method if acceptable turn-around times are to be 
achieved. The consumables cost for the Pierce method has been kept low by 'regenerating' 
and re-using the columns which are sold as single-use, disposable items. In the past, this in- 
house treatment of columns has kept the cost per test low. It is, however, extremely labour 
intensive and current increases in workload cannot be sustained without increases in 
staffing. To use the Pierce columns correctly, as disposable items, would increase the 
consumables cost from £0.30 to £5.41 per test, equating to an increase in consumables cost 
of £58,428 per annum. Purchase of the GHb-100 analyser for this assay would increase the 
consumables cost to £0.59 per test which equates to an increase of £3,132 per annum. The 
capital cost of the GHb-100 analyser is £15,450 plus VAT if purchased before the end of 
March 1998. The revenue cost of consumables of the analyser, based on a workload of 
10,800 per annum is £6,372 and the annual maintenance charge would be £1,810 after the 
one year warranty period. See sections 3.6 and 3.7 for detailed methodologies.
1.6.5 Preferred Hospital Methods
For each laboratory the choice of method will depend on several factors, including 
set-up costs, the number of samples to be analysed, sample-handling details, running costs, 
and even the characteristics of the patient population (e.g. prevalence of 
haemoglobinopathies).
Because they are easy to automate, inspite of their many limitations, ion-exchange 
methods predominate. The "superior" affinity methods, until now, have proved difficult to 
automate and for this reason their use has declined. In addition to the Drew GHb-100
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analyser. Primus, an American company have recently introduced an automated affinity 
method based on HPLC. If the machines prove satisfactory affinity methods may again 
become popular.
1.6*6 Problems of Standardisation with Glycohaemoglobin Methods
Each assay method measures glycohaemoglobin in a slightly different manner and 
assay conditions will differ between laboratories. In addition, there is no consensus on either 
a reference method or a single GHb standard. Thus, the actual numbers generated 
(including reference ranges) in one laboratory cannot be compared easily with numbers 
generated in another laboratory, even if the same basic assay is used. For example, a test 
value of 9% GHb in one laboratory might indicate that concentrations of blood glucose had 
been near the normal range, but in another laboratory might indicate high results. Under 
these less than ideal circumstances, each laboratory that performs GHb determinations must 
work closely with the medical practitioners who order the tests, to assure proper 
interpretation of results
A report published by the National Institute of Health Diabetes Data Group Expert 
Committee on glycosylated haemoglobin, suggests that intra-and interassay CVs of 5% are 
attainable, and should be achieved in any laboratory performing these measurements (171).
Different methods measure a range of different glycated fractions and the lack of a 
recognised standard has resulted in a large discrepancy in the results from the different 
systems. It is therefore at present impossible to define accuracy. Performance in external 
quality assessment can only be used to assess precision of a specific method within a 
laboratory (Table 6) or bias of one method from another.
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Table 6. Within laboratory precision and between laboratory agreement for the major glycohaemoglobin 
methods. Data from the U.K. National External Quality Assurance Scheme (NEQAS) for 
Glycohaemoglobin (172).
Within Laboratory Between Laboratory
Precision (%CV) Agreement (%CV)
Within-batch Between-batch Normal result High result
6-14* 6-14*
5-10 2-5
9-14 5-9
9-12* 9-12*
4-8 3-9
10-12 7-8
12-16* 12-16*
* No recent returns. Between laboratory agreement based on historical data.
One important result of assay imprecision is spurious widening of the reference 
internal, thereby limiting the usefulness of GHb to fine tune diabetic therapy.
There being no consensus on either a reference method or GHb standard, 
laboratories have a wide variety of quality control procedures. The materials are most often 
lyophilised haemolysates that are reconstituted in the local laboratory and used over several 
days or weeks. The stability of these materials has not, for the most part, been well 
documented. GHb standards called 'calibrators' are available from at least one manufacturer 
(Primus Corporation, Kansas City, USA).
Many laboratories monitor assay precision by using locally prepared controls -
usually haemolysates of whole blood or packed erythrocytes from normal and diabetic
samples (155,156). For laboratories that use ion-exchange chromatographic methods,
controls must be stored -70oC or colder to prevent gradual increases in the HbAja + y
fraction (155,156). With proper storage conditions, controls will remain stable over many
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HhA^
Ion-exchange
Chromatography 3-10 4-12
HPLC 1-3 2-4
Electrophoresis 3-10 6-13
HbAlc
Ion-exchange
Chromatography 2-8 3-4
HPLC 1-3 2-4
Immunoassay 2-8 2-10
GHb
(Manual) Affinity
Chromatography 3-5 3-8
months. Most laboratories include locally prepared controls in each assay, in addition to any 
commercial controls or standards. Manufacturers of commercial quality control materials 
face many of the same difficulties as local laboratories do in maintaining a high degree of 
long-term precision. One important facet of quality control is the establishment of non­
diabetic reference interval in each laboratory that performs GHb determinations. In doing 
so, one must scrupulously avoid including samples from individuals with diabetes or even 
mildly impaired glucose tolerance, or with other factors such as haemoglobinopathies and 
anaemia's, that might affect glycohaemoglobin concentration.
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2.0 AIMS OF THE PROJECT
The Clinical Pathology Department of the Royal Sussex County Hospital carries out 
about 10,800 glycohaemoglobin measurements every year. At present the manual Pierce 
affinity column method is used. This procedure is very labour intensive and consequently we 
have been considering ways of automating the test. Most of the established dedicated 
automatic analysers measure HbA|c by ion-exchange. As we choose to measure total 
glycohaemoglobin, it was our intention to develop an 'in-house* automated affinity method. 
During discussions with HPLC column suppliers we learned that Drew Scientific were 
developing an analyser based on the affinity procedure. Following our inquiries. Drew 
Scientific invited us to carry out the first clinical trials and evaluation for their pre- 
production analyser.
For the second part of my work I have studied GHb in long-term peritoneal dialysis 
patients. Patients undergoing peritoneal dialysis, for the treatment of chronic renal failure, 
are subject to high peritoneal concentrations of glucose (present in the dialysate) and it was 
thought that this could affect the patients GHb status. Because glycation products continue 
to form following a glucose challenge even after blood glucose has returned to normal, I 
hypothesised that I would find raised GHb concentrations in long-term CAPD patients.
The research conformed to the ethical standards set out by the Royal Sussex County 
Hospital for research.
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3.0 EXPERIMENTAL-METHODS AND MATERIALS
The need was for an automated affinity method for the measurement of total 
glycohaemoglobin, that would cause minimal disruption to our established procedures. It 
was desirable to maintain our existing blood collection, sample preparation and reference 
ranges. Drew Scientific recommend dilution of whole blood in deionised water, while our 
existing method uses packed cells haemolysed in dilute Triton X-100. Drew Scientific also 
recommended calibrating their instrument using the diabetes control and complications trial 
(DCCT) (173) referenced HbAlc standards. We decided to find calibrants that, if possible, 
would give similar results to our existing method and hence avoid the considerable 
disturbance that would result from having to alter our existing reference value.
The glucose containing peritoneal dialysis solutions used in CAPD contain from 
13.6 to 38.6 g/1 of glucose. During CAPD large quantities of glucose are absorbed from the 
dialysate each day. This may provide a valuable source of energy to malnourished patients, 
but it may also cause further disturbances in the already abnormal uraemic metabolism of 
lipids, carbohydrates, proteins and amino acids. In this study I present results on the effects 
of CAPD in renal patients with special regard to the effects of glucose absorption from the 
peritoneal fluids on glycohaemoglobin concentrations.
3.1 Subjects
The total number of renal patients on CAPD studied = 67. The number of male 
CAPD patients = 42 ( 32 non-diabetic, 10 diabetic). The number of female CAPD patients = 
25 ( 20 non-diabetic, 5 diabetic).
Routine blood samples for the measurement of glycohaemoglobin were used for the 
evaluation of the GHb-100 analyser from Drew Scientific. The samples were mainly 
obtained from the out-patients department at the Royal Sussex County Hospital, Brighton. 
Some glycohaemoglobin samples were also obtained from the hospital wards and general
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practitioners.
Routine blood samples for the measurement of renal function tests (including urea 
and creatinine) on renal patients receiving CAPD treatment in the renal dialysis unit at the 
hospital mentioned above were intercepted after the routine test analysis had been 
completed. Glycohaemoglobin was then measured on these samples to obtain data for this 
project. Sixty routine biochemistry samples from non-diabetic, non-renal patients were 
selected after the requested tests were completed for use as controls. Number of male 
control patients — 40, number of female control patients = 20. Forty routine biochemistry 
samples from diabetic, non-renal patients were also used as controls when the requested 
tests were completed. Number of male control patients = 20, number of female controls = 
20.
Random plasma glucose measurements were carried out routinely on the renal 
patients on CAPD by the renal physician. The results of urea, creatinine, and plasma glucose 
on renal patients on CAPD were obtained from the stored data in the laboratory computer.
Three to five 2 litre bags of commercially available dialysate solution were instilled 
each day into the peritoneal cavity of the renal patients on CAPD by the method of 
Oreopolous et al. (174). The number of exchanges containing either (1.36%, 2.27%, 3.86% 
glucose solutions and 7.5% w/v icodextrin was prescribed by the renal physician according 
to the need for fluid removal in each patient.
Patients on icodextrin used glucose containing CAPD fluids for the day-time dwells 
and 7.5% icodextrin in place of a bag of glucose solution for the overnight dwell, while 
patients on the glucose containing CAPD fluids used glucose solutions for the day-time and 
overnight dwells.
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3.2 Sample Preparation
The blood samples for glycohaemoglobin measurement were taken into 7 ml lithium 
heparin tubes. The blood samples for renal function tests on renal patients receiving CAPD 
treatment and blood samples for routine biochemistry tests on non-diabetic, non-renal 
patients and diabetic, non-renal patients (controls) were also taken into 7 ml lithium heparin 
tubes. The blood samples for routine random plasma glucose measurements on the renal 
patients on CAPD were taken into 5 ml fluoride-oxalate containers.
On arrival at the laboratory the blood samples were centrifuged at 3000 rpm for 15 
minutes. The routine samples for renal function tests and plasma glucose on CAPD patients 
and the control samples were analysed on the day of receipt. Samples for glycohaemoglobin 
measurement were stored at 4°C and analysed within 3 days of receipt.
The renal function tests and plasma glucose measurements were analysed on the 
Vitros 950 analyser (Ortho-Clinical Diagnostics, Amersham, Buckinghamshire, HP7 OJS). 
The reaction sequence of the urea, creatinine, and glucose test methodologies are 
summarised below.
Reaction sequence for urea on the Vitros 950 analyser
urease
H2NCONH2 + h20 ----- > 2NH3 + C02
NH3 + ammonia indicator — > dye
Reaction sequence for creatinine on the Vitros 950 analyser
creatinine amidohydrolase
creatinine + H20 > creatine
creatine amidohydrolase
creatine + H20 > sarcosine + urea
sarcosine oxidase
sarcosine + 0 2 + H20 > glycine + formaldehyde + H20 2
peroxidase
H20 2 + leuco dye > dye
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Reaction sequence for glucose on the Vitros 950 analyser
glucose oxidase
P-D-glucose + O2 + H20  — ---------------------------------------- > D-gluconic acid + 8 2O2
peroxidase
2H2O2 + 4-aminoantipyrine + 1,7-dihydroxynaphthalene----------------------------- > red dye
3.3 Equipment
1) Columns.
1) Pre-packed Glycotest II Analytical Columns from Pierce and Warriner, Cambridge, U.K.
ii) GHb-100 analyser columns from Drew Scientific, Ltd., Barrow-in-Furness, Cumbria 
LAI 4 4QR.
2) 7 ml lithium heparin blood collection tubes. Vacutainer. Brand sterile interior from 
Becton Dickinson Vacutainer Systems, France.
3) 5 ml lithium fluoride-oxalate blood collection tubes. Vacutainer. Brand sterile interior 
from Becton Dickinson Vacutainer Systems, France.
4) Absorbance spectrophotometer. Pharmacia Ultrospec III UV- visible spectrophotometer 
was obtained from Pharmacia Ltd. Pharmacia L.K.B., Milton Keynes, Buckinghamshire, 
MK9 3HP.
5) Centrifuge Eppendorf Centrifuge 5416. EppendorfLtd., Cambridge, U.K.
6) Balance Sartorious Handy Balance, resolution 0-1 mg. Anachem Ltd., Luton, 
Bedfordshire, LU2 06B.
7) L.K.B. diluter. Wallac, Finland.
8) Pipettes Variable volume Gilsen automatic pipettes. Anachem Ltd., Luton, 
Bedfordshire, LU2 06B.
9) flHh-l 00 analyser Drew Scientific Ltd., Barrow-in-Furness. Cumbria LAI4 4QR.
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3.4 Chemicals
1) Triton X-100 Aldrich Chemical Co. Ltd, Gillingham, Dorset, U.K.
2) All other chemicals were obtained from The British Drug Houses Ltd. BDH Laboratory 
Group, Pool, Dorset, U.K.
3.5 Data Analysis
Statistical analysis of the data was carried out using Minitab and Microsoft Excel linear and 
Demming's regression.
3.6 Glycohaemoglobin Measurement by the Pierce Affinity 
Chromatography Method.
3.6.1 Principle:- See AfiBnity Chromatography
3.6.2 Reagents and Columns
1) Columns. Pre-packed Glycotest II Analytical columns from Pierce and Warriner were 
used. They were stored at 4°C. After regeneration the columns could be re-used 16 times.
2) Haemolysing reagent 0.1% Triton. 1 ml of Triton X-100 was dissolved in 1 litre of 
deionised water and stored at room temperature.
3) Wash buffer 250 mmol/1 ammonium acetate, 50 mmol/1 magnesium chloride, pH 8.3.
35.5 g of anhydrous ammonium acetate and 20.3 g of magnesium chloride hexahydrate 
were dissolved in 1.5 litres of deionised, and adjusted to pH 8.3 using 1 mol/1 of sodium 
hydroxide and made up to 2 litres. The wash buffer was stored at 4°C.
4) Elution buffer 200 mmol/1 Sorbitol, 50 mmol/1 EDTA in 100 mmol/1 Tris buffer, pH
8.3. 36.4 g ofD-Sorbitol, 12.2 g of Tris(hydroxymethyl)methylamine and 18.6 g disodium 
EDTA dihydrate were dissolved in about 800 ml of deionised water. This was adjusted to 
pH 8.3 using 1 mol/1 hydrochloric acid and made up to 1 litre and stored at 4°C.
5) Regeneration solution. 1% hydrochloric acid. 5 ml of concentrated hydrochloric acid 
were added to 500 ml of deionised water and stored at room temperature.
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3.6.3 Quality Control
1) Tn-hnuse low control - From routine batches, 12 samples with glycohaemoglobin results 
of 7-10% were chosen. Haemolysates were prepared, pooled and frozen in 200 ml aliquots. 
Ranges of mean +/- 2 SD were established by assaying in duplicate on 20 batches, giving 40 
results.
2) Tn-hnuse high control:- From routine batches, 12 samples with glycohaemoglobin 
results of 17-20% were chosen. Haemolysates were prepared, pooled and frozen in 200 ml 
aliquots. Ranges of mean +/- 2 SD were established by assaying in duplicate on 20 batches, 
giving 40 results.
3) Carry overs. Two samples, one with around 5% glycohaemoglobin and one around 10% 
glycohaemoglobin were chosen from the previous batch. The carry overs were used as 
another internal quality control check.
3.6.4 Assay Procedure
1) A batch for glycohaemoglobin assay usually consisted of 44
samples plus low and high controls at each end and two samples earned over from the
previous batch, i.e. 50 tests. The usual arrangement of the batch was>
Position Control 
1+49 Low control
2 + 50 High control
17 Low Carryover
27 High Carryover
2) One set of 5 ml tubes were labelled 3-48 for the haemolysis step. Two sets of test tubes 
were each labelled from 1-50, to collect the fractions from the chromatography.
3) The low and high controls were already haemolysed. Using the LKB diluter, 100 
microlitres of packed red cells from each patient and carryover sample were diluted with 2.0 
ml of haemolysing reagent into its corresponding 5 ml tube. The sample was taken from the 
centre of the cells to avoid the buffy layer. The haemolysates were vortex mixed to ensure 
complete haemolysis.
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4) The controls were allowed to thaw and were mixed well.
5) The wash and elution buffers were warmed to between 19°C and 21°C. The reagent 
temperature was maintained at this temperature throughout the assay. The current set of 
columns were taken from the fridge and allowed to come to room temperature.
6) Then regeneration solution in which the columns were stored was discarded. Each 
column was primed with 2.5 ml pre-warmed wash buffer. When fully drained the columns 
were transferred to the first set of labelled test tubes and the priming solution discarded.
7) Using the LKB diluter, 50 microlitres of each haemolysate were picked up and dispensed 
on to the top of the appropriate column with 0.5 ml wash buffer. This was allowed to soak 
in completely and was left for a further 15 minutes.
8) 2.5 ml of wash buffer were added to each column, followed by a further 2.5 ml when 
there was room. This was allowed to drain completely. The eluate was mixed thoroughly. 
This was the non-glycohaemoglobin (wash) fraction.
9) Keeping the columns in order, they were transferred to the second set of test tubes. 3.0 
ml of pre-warmed elution buffer were added and allowed to drain completely. The eluate 
was mixed thoroughly. This was the glycohaemoglobin (elution) fraction.
10) The Ultrospec m  spectrophotometer, printer, and computer were switched on. The 
computer (IBM, model P52) was pre-programmed to calculate the % GHb from the elution 
and wash fractions, and also to set the wavelength to 414 nm.
11) Samples were selected to act as carryovers on the next batch, and the carryover 
controls were placed with the next batch of samples.
12) After analysis samples were stored at 4°C for one week before disposal in an autoclave 
bin,
13) After use the columns were transferred to their storage rack. Each column was washed
with 2.5 ml of deionised water and the (trainings discarded. Then 2 x 4.5 ml of the
regeneration solution was applied to each column which was then stored wet at 4°C.
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14) Columns were discarded at or before their 16* use (166).
3.6.4.1 Calculation
The % glycohaemoglobin was calculated using the following equation:-
% GHb = A414nm Elution
(A414 nm Wash x 5.55/3) + A 414 nm Elution
This calculation was done automatically by the ultrospec computer. A = absorbance.
3.6.4 2 Result Range and Interpretation
The result ranges for glycohaemoglobin and their interpretation using the Pierce affinity 
chromatography method are listed below.
These ranges and interpretations were set on the basis of locally-determined normal range, 
and were agreed with Dr N Vaughan, Consultant Endocrinologist at the Royal Sussex 
County Hospital.
3.7 Glycohaemoglobin Measurement by the Drew Scientific GHb-100 
Affinity LPLC Automated Analyser
3.7.1 Principle See Affinity Chromatography
3.7.2 Reagents and Columns
Column GHb-100 analyser columns obtained from Drew Scientific.
Reagent A GHb-100 analyser reagent (wash buffer) obtained from Drew Scientific.
Kfiflgpnt R GHb-100 analyser reagent (elution buffer) obtained from Drew Scientific. 
Sample vials. GHb-100 sample vials obtained from Drew Scientific.
Result range 
<  2.0%
2.01-3.1%
3.11-4.7%
4.71-7.5%
7.51-8.5%
8.51-9.7%
9.71-13.0%
13.01-17.0% 
> 17%
Interpretation
Very low; hypoglycaemia very likely
Low; serious risk of hypoglycaemia in diabetic patients
Normal, but risk of hyopglycaemia in diabetic patients
Normal; excellent diabetic control
Just above normal, but good diabetic control
Above normal, but acceptable diabetic control
High, poor diabetic control
Very high; extremely poor diabetic control
Very high; uncontrolled diabetes
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3.7.3 Quality Control
Biorad 1 (low) and Biorad 2 (high) controls wore obtained from Biorad Laboratory 
Ltd., Bio-Rad House, Maylands Avenue, Hemel Hempsted, Herts., HP2 7TD. The controls 
were provided in the lyophilizcd form for increased stability. On receipt the controls were 
reconstituted with 0.5 ml of deionised water, and allowed to stand for 10 minutes. Before 
sampling, the vial was gently swirled to ensure homogeneity. The controls were diluted 
using the LKB diluter set at 10 microlitres to pick up the control and 1 ml to pick up the 
deionised water. The controls were mixed for homogeneity and stored at -20°C until 
required. The GHb-100 analyser was calibrated using assigned calibrant values of Biorad 1 
= 3.8% Biorad 2 =-10.0%, unless otherwise stated.
1) Tn-hnuse low control:- From routine batches, 12 samples with glycohaemoglobin results 
of 5.0-6.5% were chosen. Haemolysates were prepared, pooled and frozen in 2 ml 
aliquots.
2) Tn-hnuse high controls:- From routine batches, 12 samples with glycohaemoglobin 
results of 9.5-10.5% were chosen. Haemolysates were prepared, pooled and stored in 2 ml 
aliquots.
3) Carryovers. Two samples, one with around 5% glycohaemoglobin and one around 10% 
glycohaemoglobin were chosen from the previous batch. The carryovers were used as an 
internal quality control check.
3.7.4 Primus Calibrant
Primus 1 (normal) and Primus 2 (high) calibrants were obtained from Primus
Corporation, 7235 Central Avenue, Kansas City, USA The calibrants were provided in the
lyophilized form for increased stability. On receipt the calibrants were reconstituted with
400 microlitres of deionised water and allowed to stand for 10 minutes. Before sampling,
the vial was gently swirled to ensure homogeneity. The calibrants were diluted using the
LKB diluter set at 10 microlitres to pick up the calibrant and 1 ml to pick up deionised
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water. The calibrants were mixed for homogeneity and stored at -20°C until required. 
Primus calibrator values ( set by the manufacturer)
HbAlc Total GHb
Component HPLC Affinity(176)
HPLC Affinity(175)
Lot no. 1056 Calibrator 1 5.8% 7.0%
Lot no. 1057 Calibrator 2 13.3% 19.7%
3.7.5 Assay Procedure
1) A batch of glycohaemoglobin samples normally consisted of 50 or 99 samples, according 
to the assay requirements. Depending on the circumstances, the GHb-100 analyser was 
flushed with new reagents and /or calibrated before analysing the samples. After each 
sample analysis the results were printed. When the batch was complete a summary of results 
was printed. Each GHb-100 glycohaemoglobin kit consisted of a column, reagents A and B 
and sample vials to provide 500 assays. Each sample took approximately 4 minutes to 
complete.
The usual arrangement for controls in a The usual arrangement for controls in a
50 sample batch was:- 99 sample batch was:-
Position Control Position Control
1+49 Biorad 1 (Low control) 1+98 Biorad 1 (Low control)
2+50 Biorad 2 (High control) 2+99 Biorad 2 (High control)
17 Carryover (low) 49 Carryover (low)
27 Carryover (high) 50 Carryover (high)
2) One set of 5 ml tubes were labelled from 3-48, or 3-97 depending on the assay 
requirements.
3) The Biorad 1 and Biorad 2 controls were already haemolysed. Using the LKB diluter, 10 
microlitres of packed cells from each patient and carry over sample were diluted with 2 ml 
of deionised water into its corresponding 5 ml tube. The sample was taken from the centre 
of the cells to avoid the buffy layer. The haemolysates were vortex mixed to ensure 
complete haemolysis.
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4) The heamolysates were then assayed immediately, but could be stored at 4°C for 3 days 
according to the manufacturer (Drew Scientific).
5) The controls (Biorad 1 and Biorad 2) were allowed to thaw and mixed well.
6) 1 ml of the haemolysate was pipetted into the appropriate sample vial placed on the 
autosampler tray.
7) The GHb-100 analyser was programmed to carry out the required number of tests, i.e. 
50, or 99 samples.
8) The GHb-100 analyser was programmed to carry out a background check on deionised 
water and if necessary the GHb-100 analyser was programmed for calibration. The calibrant 
used was Biorad 1 ( assigned value GHb = 3.8%) and Biorad 2 ( assigned value GHb = 
10.0%).
9) The background was checked and when necessary the calibration was checked before 
proceeding with the assay.
10) When the GHb-100 analyser completed the batch, a continual flow of reagent A was 
maintained at 50 microlitres per minute.
3.7.5.1 Calculation
A table of results were produced with the ratio of GHb to total haemoglobin.
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4.0 EVALUATION AND RESULTS OF THE GHb-100 
ANALYSER FROM DREW SCIENTIFIC
4.1 Effect of Haemoglobin concentration on GHb Results
The haemoglobin (Hb) concentration interferes with the ion-exchange and 
electrophoresis methods (134,137,149). Normally physiological variations in haemoglobin 
concentration will not give rise to large deviations, but careless handling during preparation 
of the haemolysate can enhance the effect. The application of greater than recommended 
haemolysate concentration to commercially available ion-exchange mini-columns can shift 
the elution profile sufficiently to cause anamolous results because of poorer separation 
between the slow and fast fractions.
Haemolysate concentration is even more critical in the TEA colorimetry, because 
results are expressed as nanomoles of hydroxymethyl furfural per 10 mg of haemoglobin. 
Any variation from the assumed quantity per test will affect the resulting values 
proportionately (149). The affinity interaction, however, appears to be relatively 
independent from such errors since the final glycohaemoglobin concentrations are expressed 
in proportional and not absolute terms (166).
A study of the effect of Hb concentration on GHb results was carried out on the 
GHb-100 analyser using a series of haemoglobin dilutions. 10 samples with GHb results of 
around 10% were collected (9.6%, 9.4%, 10.3%, 10.4%, 10.2%, 9.9%, 9.6%, 9.6%, 
10.2%, 9.4%). The plasma from the 10 samples was aspirated and pooled together in a 
container. The remaining packed cells were pooled together in a separate container.
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The haemoglobin dilutions were made using the LKB diluter as follows:-
Packed Volume of Volume of Total
Cell Volume Packed Cells Plasma Volume
(%) (microlitres) (microlitres) (microlitres)
10 100 900 1000
20 200 800 1000
30 300 700 1000
40 400 600 1000
50 500 500 1000
60 600 400 1000
70 700 300 1000
80 800 200 1000
90 900 100 1000
100 1000 0 1000
The haemoglobin dilutions were then treated as whole blood samples. 10 microlitres of the 
haemoglobin dilutions were haemolysed with 1 ml of deionised water using the LKB diluter 
and mixed thoroughly. The haemoglobin dilutions were then placed in the sample rack of 
the GHb-100 analyser and the machine was programmed to carry out GHb assay on the 
dilutions.
The effect of Hb concentration on GHb results can be seen in Table 7. A packed 
cell volume (PCV) from 30% to 70% shows a very small increasing trend in GHb results 
(0.3% GHb).
Table 7 Effect of Hb concentration (PCV%) on GHb%
PCV% GHb%
10 —
20 —
30 8.7
40 8.8
50 9.0
60 9.1
70 9.0
80 9.2
90 9.5
100 9.8
— Error (low sample concentration)
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4.2 Effect of Using 1% Triton X-100 as a Haemolysing Reagent
The Pierce affinity method requires 1% Triton X-100 as a Haemolysing reagent, 
while Drew Scientific recommend deionised water as a haemolysing reagent.
Triton X-100 is a detergent and a more powerful haemolysing reagent than 
deionised water. A study was carried out to determine the effect of using 1% Triton X-100 
as a haemolysing reagent on the GHb-100 analyser. A sample with a known GHb result was 
used in the evaluation. 10 microlitres of whole blood was haemolysed with 1 ml of 1% 
Triton X-100 and deionised water respectively, using the LKB diluter. Figure 3 shows a 
typical GHb chromatogram of the haemolysate analysed by the GHb-100 analyser using 
deionised water as a haemolysing reagent. Figure 4 shows a GHb chromatogram of the 
haemolysate analysed by the GHb-100 analyser using Triton X-1QQ as a haemolysing 
reagent.
It can be seen from Figure 3 that when deionised water is used as a haemolysing 
reagent there is good separation of glycohaemoglobin (peak 2) from total haemoglobin 
(peak 1). It can be seen from Figure 4 that when Triton X-100 is used as a haemolysing 
reagent, the column became adversely affected and could not separate glycohaemoglobin 
from total haemoglobin. Once the column was damaged by the use of Triton X-100, the 
separation problem with the column could not be rectified. The damaged column was 
discarded and replaced with a new column. The use of Triton X-100 as a haemolysing 
reagent for the GHb-100 analyser was discontinued and deionised water - as recommended 
by Drew Scientific was used thereafter.
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Fipjne 3 A typical GHb chromatogram of the haemolysate analysed by the GHb-100 analyser «King 
deionised water as the haemolysing reagent (key provided).
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[1] Display Area 
[21 Count
[3] Laboratory Name
[4] Status Window
[5] Date and Time
[6] Kit Status
[7] Results Window
[8] Batch Information
This area of the screen is used to display traces and prompting messages when 
operator action is required.
This displays the assay count number.
This displays the laboratory name that has been programmed into the parameter 
file.
Three boxes which display current activities of the system.
The current date and time.
This displays the number of tests remaining in numerical and visual form 
This is used to display the numerical results of the analysis and messages for the 
operator.
Displays the progress through the batch, e.g. Batch : 12 - 23 B(C4) m«mS that 
the current sample is 12, the last sample in the Hatçh is 23. Background 
subtraction is in force. C4 is the background well. (Not shown here).
[9] Temperature Display Displays peltier temperature and current status of the pettier device.
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Figure 4 A GHb chromatogtam of the haemolysate analysed by the GHb-100 analyser using 
Tnton X-10P. as a haemolysing reagent
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4.3 Packed Cells versus Whole blood
The Pierce method uses packed cells for the preparation of haemolysates, while 
Drew Scientific recommend whole blood for the preparation of haemolysates for use on the 
GHb-100 analyser. Packed cells are more convenient to use for the measurement of GHb in 
our laboratory as most of the whole blood samples are centrifuged on receipt to obtain 
serum or plasma, which is then used for the measurement of various other biochemical 
analytes. In addition, the use use of packed cells eliminates the need to mix the samples 
prior to haemolysing. The whole blood samples require thorough mixing prior to 
haemolysing to obtain a homogenous sample as cells tend to settle out on standing.
A study of packed cells versus whole blood was carried out on the GHb-100 
analyser. Drew Scientific recommend 10 microlitres of whole blood to be haemolysed with 
1 ml of deionised water. Forty samples with known GHb results were haemolysed in two 
sets using the LKB diluter. The whole blood haemolysates were prepared first. The whole 
blood samples were then centrifuged at 3500 rpm for 15 minutes to obtain the packed cells 
for the packed cell haemolysates.
a) The first set of haemolysates were made using 10 microlitres of whole blood with 1 ml of 
deionised water.
b) The second set of haemolysates were made using 10 microlitres of packed cells with 2 ml 
of deionised water.
Using linear regression, the results of packed cells versus whole blood was 
calculated. The results of the study of packed cells versus whole blood is shown in Figure 
5. It can be seen from Figure 5 that there is a good correlation between the GHb results 
obtained from the packed cells and those from whole blood samples, n = 40, y = 0.9572x - 
0.0987 where y = whole blood GHb (%) x = packed cells GHb (%), r = 0.9904.
To see individual results for the study of packed cells versus whole blood see Table 1 in 
Appendix.
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4.4 Precision-run Study
A report published by the National Institute of Health Diabetes Data Group Expert 
Committee on glycosylated haemoglobin, suggests that intra and interassay CVs of 5% are 
are attainable, and should be achieved in any laboratory performing these measurements 
(171).
A precision-run study was carried out on the GHb-100 analyser from Drew 
Scientific. Two samples with known GHb results were used in the precision study 
evaluation.
a) The first sample with a known low GHb value was analysed 40 times. 10 microlitres of 
packed cells were haemolysed with 2 ml of deionised water.
b) The second sample with a known high GHb value was analysed 53 times. 10 microlitres 
of packed cells were haemolysed with 2 ml of deionised water.
The results of the precision-run study are shown in Tables 8 and 9. It can be seen 
from Tables 8 and 9 that the GHb-100 analyser is a very precise instrument for measuring 
both low and high GHb ranges.
List of statistical abbreviations used:-
N = number
MEAN = mean value
MEDIAN = median value
TRMEAN = truncated mean value
STDEV = standard deviation
SEME AN = standard error of mean value
MIN = minimum value
MAX = maximum value
Q1 = 1st quartile value
Q3 = 3r(* quartile value
% CV = coefficient of variation (%)
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a) Low GHb Precision-run
Table 8 The GHb results (%) obtained for the low GHb precision-run
n GHb % n GHb% n GHb % n GHb%
1 5.5 11 5.6 21 5.6 31 5.8
2 5.6 12 5 7 22 5.7 32 5.7
3 5.5 13 5.6 23 5.8 33 5.7
4 5.7 14 5.7 24 5.8 34 5.8
5 5.8 15 5.7 25 5.8 35 5.8
6 5.6 16 5.8 26 5.7 36 5.6
7 5.6 17 5.6 27 5.7 37 5.8
8 5.6 18 5.7 28 5.8 38 5.8
9 5.7 19 5.8 29 5.8 39 5.9
10 5.7 20 5.7 30 5.8 40 5.9
n = 40 MEAN = 5.7125 MEDIAN —5.7000 TRMEAN = 5.7139 STDEV -  0.0992
SEME AN = 0.0157 MIN = 5.5000 MAX = 5.9000 Q1 = 5.6000 Q3 = 5.8000 
The calculated % CV for the low GHb precision-run = 1.74%.
c) High GHb Precision-run
Table 9 The GHb results (%) obtained for the high GHb precision-run.
n GHb% n GHb% n GHb % n GHb%
1 10.6 15 10.7 29 10.8 43 10.9
2 11.0 16 10.7 30 11.0 44 11.0
3 11.1 17 10.6 31 11.0 45 11.0
4 10.9 18 10.7 32 11.0 46 11.0
5 11.1 19 10.7 33 10.8 47 11.0
6 11.1 20 10.4 34 10.7 48 11.0
7 11.2 21 10.6 35 10.8 49 11.1
8 11.1 22 10.8 36 11.1 50 11.0
9 11.2 23 10.8 37 11.1 51 10.9
10 11 1 24 10,7 38 10.9 52 11.0
11 10.7 25 10.9 39 11.0 53 10.7
12 10.8 26 10.8 40 11.1
13 10.6 27 11.0 41 11.1
14 10.7 28 10.8 42 10.9
n = 53 MEAN = 10.885 MEDIAN = 10.900 TRMEAN = 10.891 STDEV = 0.192 
SEME AN = 0.026 MIN = 10.400 MAX = 11.200 Q1 = 10.700 Q3 = 11.000
The calculated % CV for the high GHb precision-run = 1.76%
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4.5 Between-batch Precision Study
A study of between-batch precision was carried out on the GHb-100 analyser. In- 
house low and high controls were used to assess the between-batch precision of the GHb- 
100 analyser during the evaluation period. To prepare the in-house controls - see section
3.7.3,
The GHb results of the between-batch precision on the in-house low and high 
controls are shown in Table 10.
The between-batch results of the in-house low and high controls are summerised below. 
In-house low control
n = 89 MEAN = 6.3697 MEDIAN = 6.3000 TRMEAN = 6.3654 STDEV = 0.2986 
SEMEAN = 0.0317 MEN = 5.8000 MAX = 7.0000 Q1 =6.1000 Q3= 6.6000 
The calculated % CV = 4.69%.
In-house high control
n=  89 MEAN = 9.6831 MEDIAN = 9.7000 TRMEAN = 9.6728 STDEV = 0.3283 
SEMEAN = 0.0348 MIN = 9.0000 MAX = 10.9000 Q1 = 9.4000 Q3 = 9.9000 
The calculated % CV = 3.39%.
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Table 10. Between-batch precision of in-house low and high controls
Batch no. Low 
GHb (%)
High 
GHb (%)
Batch no. Low 
GHb (%)
High 
GHb (°/
1 6.7 10.2 46 6.1 9.4
2 7.0 10.4 47 6.3 9.6
3 6.9 9.9 48 6.4 9.8
4 6.5 9.8 49 6.3 9.5
5 6.8 9.8 50 6.3 9.4
6 6.9 10.0 51 6.3 9.5
7 6.7 9.9 52 6.2 9.5
8 6.5 9.8 53 6.6 10.1
9 6.7 10.1 54 6.8 10.0
10 6.6 9.9 55 6.1 9.5
11 6.8 10.2 56 6.6 10.0
12 7.0 10.4 57 6.7 9.8
13 6.4 10.0 58 6.9 10.1
14 6.6 10.1 59 6.6 10.9
15 6.4 9.7 60 6.8 10.0
16 6.2 9.4 61 6.1 9.2
17 7.0 9.7 62 6.0 9.2
18 6.3 9.9 63 6.0 9.4
19 6.2 9.7 64 6.0 9.2
20 6.3 9.6 65 6.2 9.5
21 6.3 9.5 66 6.3 9.6
22 6.5 9.8 67 6.1 9.4
23 6.2 9.5 68 6.0 9.5
24 6.3 9.5 69 6.2 9.5
25 6.2 9.7 70 6.5 9.6
26 6.7 10.1 71 6.4 9.7
27 6.7 9.6 72 6.4 9.7
28 6.4 9.7 73 6.4 9.7
29 6.6 9.9 74 6.4 9.7
30 6.7 9.9 75 6.5 9.9
31 6.6 9.8 76 6.2 9.8
32 6.7 10.0 77 5.9 9.0
33 6.7 9.9 78 5.8 9.0
34 6.7 10.1 79 6.3 9.4
35 5.9 9.6 80 6.1 9.4
36 6.3 10.2 81 6.0 9.4
37 6.1 9.4 82 6.1 9.4
38 6.1 9.2 83 6.3 9.7
39 6.5 9.8 84 6.1 9.5
40 6.2 9.7 85 6.2 9.3
41 6.1 9.3 86 6.3 9.5
42 6.0 9.4 87 6.0 9.4
43 5.8 9.3 88 6.2 9.6
44 6.0 9.3 89 6.1 9.4
45 6.0 9.4
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4.6 Correlation Study
The Pierce affinity method of measuring GHb was used as a reference method for 
the correlation and calibration of the Drew Scientific GHb-100 analyser. A two-point 
calibration was carried out using Biorad 1 (BRI lot no. 33531, expiry date November 1998) 
and Biorad 2 (BR2 lot no. 33532, expiry date November 1998) as GHb calibrants. Biorad 
have assigned mean total haemoglobin values for the Pierce method as Follows:- 
BRI mean = 4.3% range (3.5 - 5.2%)
6R2 mean = 11.3% range (9.0 - 13.5%)
The aim of the correlation study was to determine the assigned calibration value that 
would give the best correlation of GHb results between the Pierce and Drew method. A 
good correlation between the two methods mentioned would permit our laboratory to use 
the existing reference range set for the Pierce method to be used for the Drew method, i.e. 
the GHb result reporting will not be affected.
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4.6.1 Correlation Study of Assigned Calibrant Values of BRI -  4.3% BR2 -  11.3%
The GHb-100 analyser from Drew Scientific was calibrated using the mean values 
given for the Pierce affinity method by Biorad i.e, BRI = 4.3%, BR2 = 11.3%.
The result of the correlation study using BRI = 4.3% BR2 =11.3% as the assigned 
calibrant values is shown in Figure 6. It can be seen from Figure 6 that the correlation is 
fairly good, n = 89, y = 1.0626x + 0.2464 where y = Drew GHb (%) x = Pierce GHb (%), r 
= 0.9834, p = < 0.0001. The Deming regression for the correlation studies was calculated 
using Pierce precision = 2.0% CV (166), Drew precision = 1.75% CV (mean of precision-
run study 1.74, 1.76).
The percentage difference of GHb results between the Pierce and Drew methods is 
shown in Figure 7. It can be seen from Figure 7 that there is a positive bias of GHb results 
obtained for the Drew method when using the assigned calibrant values of BRI = 4.3% 
BR2 = 11.3%. However, most of the result differences are within 0 to +15%.
The mean difference of GHb results (%) between the methods (Drew-Pierce) = 0.7719.
The mean percentage difference of GHb results (%) between the methods (Drew-Pierce 
/Pierce x 100) = 9.440.
To see individual results for the correlation study of assigned calibrant value BRI = 4.3% 
BR2 = 11.3% see Table 2 in Appendix.
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Figure 6. Correlation study of assigned cafibrant values of BRI = 4.3% BR2 = 11.3%.
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Figure 7. Percentage difference in GHb results between the Pierce and Drew methods for
the assigned calibrant values of BRI = 4.3% BR2 = 11.3%.
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4.6.2 Correlation Study of Assigned Calibrant Values of BRI = 3.8% BR2 = 10.0%
Various calibration values were assigned to BRI and BR2 to obtain a much better 
correlation of GHb results between the GHb-100 analyser and the Pierce method. By trial 
and error, a very good correlation between the two methods mentioned was obtained (BRI
= 3.8%, BR2 = 10.0%).
The result of the correlation study using BRI = 3.8% BR2 = 10.0% as the assigned 
calibrant values is shown in Figure 8. It can be seen from Figure 8 that the correlation is 
very good, n = 50, y = 1.018x -0.1034 where y = Drew GHb (%) x = Pierce GHb (%), r =
0.9806, p = <0.0001.
The percentage difference of GHb results between the Pierce and Drew methods is 
shown in Figure 9. It can be seen from Figure 9 that there is no positive or negative bias 
of GHb results obtained for the Drew method when using the assigned calibrant values of 
BRI = 3.8% BR2 = 10.0%. Most of the result differences are within -5 to +10%.
The mean difference of GHb results (%) between the methods (Drew-Pierce) = 0.0440.
The mean pecentage difference of GHb results (%) between the methods (Drew-Pierce 
/Pierce xlOO) = 0.432.
To see individual results for the correlation study of assigned calibrant value BRI =3.8% 
BR2 = 10.0% see Table 3 in Appendix.
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Figure 9. Percentage difference in GHb results between the Pierce and Drew methods for
the assigned calibrant values of BRI = 3.8% BR2 = 10.0%.
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4.6.3 Biorad versus Primus Calibrants
Towards the end of this project we came under pressure from our endocrinologist to 
report our results as T>CCT aligned'. To this end we used the Primus DCCT aligned 
calibrants (intended for their own affinity analyser) with the values of Primus 1 = 5.8%,
Primus 2 = 13.3% (175).
The GHb-100 analyser was calibrated using the assigned calibrant values of BR 1 = 
3.8% BR2 = 10.0%, and Primus 1 and Primus 2 calibrants were analysed as samples four
times each.
The GHb results for Primus 1 were: 5.1%, 5.3%, 5.3%, 5.2%. Mean result = 5.2%.
The GHb results for Primus 2 were: 14.7%, 14.7%, 14.8%, 15.0%Mean result -  14.8 A
The mean GHb results obtained for Primus 1 and 2 were quite close to the DCCT 
GHb values assigned for HbAjc by HPLC affinity (175) (Primus 1 — 5.8/6, Primus 2 
13.3%). We therefore decided to correlate the GHb results obtained on the GHb-100 
analyser using Biorad and Primus as calibrants in separate runs.
139 samples were haemolysed using 10 microlitres of packed cells with 2 ml of 
deionised water. The haemolysates were then analysed on the GHb-100 analyser using the 
assigned calibrant values of BRI = 3.8%, BR2 = 10.0%. After completion of the analysis, 
the GHb-100 analyser was calibrated using Primus 1 = 5.8%, Primus 2 = 13.3%, and the
measurements were repeated.
The results of the correlation study of Biorad versus Primus calibrants is shown in
Figure 10. n = 139, y = 0.7585x + 2.0154 where y = Primus GHb (%) x = Biorad GHb
(%), r = 0.9981, p = < 0.0001.
The percentage difference of GHb results between Biorad and Primus calibrants is
shown in Figure 11. It can be seen from Figure 11 that the Primus calibrants gave a positive 
bias for low GHb values and a negative bias for high GHb values. Most result differences 
are within -15 to +15%.
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To see individual results for the correlation study of Biorad versus Primus calibrants 
see Table 4 in Appendix.
Figure 10. Correlation study of Biorad versus Primus Calibrants
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Figure 11. Percentage difference in GHb results between Biorad and Primus Calibrants
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4.6.3.1 The Effect of Re-standardisation Using Primus Calibrants on the Existing 
reference Range for GHb
The large diabetes control and complications trial (DCCT) (173) has shown that it is 
desirable to reduce the glycohaemoglobin concentrations towards the upper end of normal. 
In order that the results from this laboratory are comparable with those elsewhere, and may 
also be clinically related with the outcomes in the DCCT, the Clinical Pathologist at the 
Royal Sussex County Hospital has now decided to realign our existing calibration (BRI = 
3.8%, BR2 = 10.0%) to be the same as that of the DCCT (Primus 1 = 5.8%, Primus 2 = 
13.3%).
The hospital laboratory will continue to use the GHb-100 affinity chromatography 
analyser for the measurement of total glycohaemoglobin (GHb), but will be calibrated in 
terms of HbA^c. The effect of this is summarised in Table 11. In the left hand column is 
shown the current ranges and associated comments which relate to the existing calibration 
(BRI = 3.8%, BR2 = 10.0%). In the third column the effect of the re-standardisation is 
calculated so as to show how the numeric results would change for the same comments. As 
these do not take account of the advantages of more intense treatment demonstrated in the 
DCCT, the new comments will be aligned with the outcomes of the DCCT as shown in the 
right hand column. The new reports will state that the results are DCCT-aligned.
The DCCT result was calculated using the formula:
DCCT result = (0.76 X GHb result calibrated using BRI = 3.8%, BR2 = 10.0%) + 2.02
84
Table 11 The effect of re-standardisation using Primus calibrants on the existing reference 
range
Existing comment and remits Existing comment. New
DCCT-recalculated DCCT
< 2% Very low, hypoglycaemia very likely. < 3.54% < 3 00%
2.01-3.1% Low, serious risk of hypoglycaemia
in diabetic patients. 3.54-4.37% 3.00-3.99%
3 .11 - 4.7% Normal, but risk of hypoglycaemia in
diabetic patients. 4.37 - 5.59% 4.00 - 4.99%
4.71 - 7.5% Normal, excellent diabetic control. 5.59 - 7.71% 5.00 - 5.99%
7.51 - 8.5% Just above normal, but good diabetic
control. 7.71 - 8.47% 6.00 - 6.99
8.51 - 9.7% Above normal, but acceptable diabetic
control. 8.47 - 9.38% 7.00 - 7.99%
Diabetic control should be improved -
at ride of complications. 8.00 - 9.49%
9.71 -13.0% High, poor diabetic control. 9.38 - 11.88% 9.50 - 10.99%
13.01 -17.0% Very high, extremely poor diabetic
control. 11.88-14.91% 11.00- 13.99%
>17.0% Very high, uncontrolled diabetes. >14.91% >13.99%
4.7 Column Life of the GHb-100 Analyser
Drew Scientific recommend that the column of the GHb-100 analyser should be 
replaced after analysing 500 samples. A study of extending the column life of the GHb-100 
analyser was carried out, to determine whether more than 500 samples can be processed on 
one column. The column was not replaced after processing 500 samples during the 
evaluation and a maximum of 720 samples were analysed before the column had to be 
replaced due to ineffective separation of the glycohaemoglobin from the total haemoglobin.
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4.8 Problems Encountered with the GHb-100 Analyser when in Routine
Use
Once the GHb-100 analysers evaluation was successfully completed and good 
correlations were obtained with the Pierce method, the GHb-100 analyser was used to carry 
out GHb measurements routinely in our laboratory.
Before the GHb-100 analyser begins analysing samples, a background (deionised 
water) is run as the reagents themselves do cause a small signal in the detector during 
chromatography due to changes in refractive index. The GHb-100 analyser then subtracts 
this background from the actual sample traces, and more reproducible chromatograms are 
obtained. When the GHb-100 analyser was in routine use, it was noticed that occasionally, 
exaggerated peaks in the background chromatograms would cause a shift in the baseline. 
The shift in the baseline was a problem of concern as it would cause falsely elevated GHb
results.
Drew Scientific were informed about the shifting baseline problem that we were 
encountering, and the chromatograms with shifting baselines were faxed to the GHb-100 
analyser engineers as requested. The engineers solved our problem by altering the computer 
software to prevent the baseline shift, i.e. the baseline now stays at the base of the sample 
peaks. Figure 12 shows a chromatogram of a background with no exaggerated peaks. This 
type of background did not cause a baseline shift. Figure 13 shows a chromatogram of a 
background with slightly exaggerated peaks. This type of background did cause a baseline 
shift.
An experiment was carried out on the GHb-100 analyser to determine which peak of 
the slightly exaggerated background was causing the problem baseline shift. Deionised 
water was analysed as a sample and the slightly exaggerated background was subtracted 
automatically by the GHb-100 analyser. Figure 14 shows a chromatogram of deionised 
water after.the slightly exaggerated background was subtracted. It can be seen from Figure
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14 that it was the first peak in the exaggerated background that was causing the baseline to 
shift.
Low and high carryovers were then analysed on the GHb-100 analyser to show the 
effect of the shifting baseline on GHb results. Figure 15 shows a chromatogram of a low 
carryover with a baseline shift. The GHb result of the low carryover was 6.5%, the shifting 
baseline increased the GHb result to 7.1%. Figure 16 shows a chromatogram of a high 
carryover with a baseline shift. The GHb result of the high carryover was 9.5%, the shifting 
baseline increased the GHb result to 10.3%.
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Figure 12 A chromatogram of a background with no exaggerated peaks.
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Figure 13 A chromatogram of a background with slight exaggerated peaks.
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Figure 14 A chromatogram of deionised water (analysed as a sample) after the slightly 
exaggerated background was subtracted.
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Figure 15 A chromatogram of a low carryover with a baseline shift. The GHb result of the 
low carryover was 6.5%, the shifting baseline increased the GHb result to 7.1%.
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Figure 16 A chromatogram of a high carryover with a baseline shift. The GHb result of the 
high carryover was 9.5%, the shifting baseline increased the GHb result to 10.3%.
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5.0 EVALUATION AND RESULTS OF THE RENAL 
PATIENTS ON CAPD TREATMENT
The continuous peritoneal absorption of glucose from glucose containing CAPD 
fluids in renal patients on CAPD treatment represents a unique situation that is not 
encountered in any other clinical situation. The reported average daily absorption of glucose 
in several studies varies between 100-200 g of glucose. This continuous supply of glucose 
may result in a variety of potentially harmful nutritional and metabolic alterations which 
have generated concern among nephrologists prescribing CAPD to their patients (8).
(Hycation and subsequent advanced glycation end products (AGE) formation, 
arising from the non-enzymatic interaction of reducing sugars with amino groups of 
biomolecules, has been recognised as a major contributing factor to diabetic complications
and the natural ageing process (74).
The use of icodextrin ( a glucose polymer) as the osmotic agent in peritoneal dialysis
fluids has the potential to reduce glycation and hence AGE formation, due to the lower 
molar concentration of icodextrin required for successful ultrafiltration (34).
A total number of 67 renal patients on CAPD were studied in this project. The 
number of male CAPD patients = 42 ( 32 non-diabetic, 10 diabetic). The number of female 
CAPD patients = 25 (20 non-diabetic, 5 diabetic). Sixty samples from non-diabetic non- 
renal patients were used as controls. Number of male control patients — 40, number of 
female control patients = 20. Forty samples from diabetic, non-renal patients were also used 
as controls. Number of male control patients = 20, number of female control patients = 20.
Samples from renal patients on CAPD and controls were haemolysed; 10 
microlitres of packed cells with 2 ml of deionised water, mixed thoroughly and the 
glycohaemoglobin concentration analysed on the Drew Scientific GHb-lQQ analyser using 
the assigned calibrant values of BRI -3 .8%  BR2 = 10.0%.
Three to five 2 - litre bags of commercially available dialysate solution were instilled
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each day into the peritoneal cavity of the renal patients on CAPD by the method of 
Oreopolous et al. (174). The number of exchanges containing either (1.36%, 2.27%, 
3.86%) glucose solutions and 7.5% w/v icodextrin was prescribed by the renal physician 
according to the need for fluid removal in each patient.
The results of the of the evaluation of GHb measurement on renal patients on CAPD are 
shown in the following tables:-
Table 12 shows the clinical and laboratory data on the renal patients on CAPD treatment 
Table 13 shows the laboratory data on controls (non-diabetic, non-renal patients)
Table 14 Laboratory data on controls (diabetic, non-renal patients)
Table 15 Random plasma glucose concentrations (mmol/1) on renal patients on CAPD 
treatment
Table 16 shows a summary of results (mean +/- 2SD) on renal patients on CAPD
treatment and control patients
It can be seen from Table 16 that male controls (non-diabetic, non-renal patients) 
have a mean GHb result of 4.8% +/- 2.2 (+/- 2SD) when n = 40. Female controls have a 
mean GHb result of 4.5% +/- 1.6 when n = 20. As expected these results show that GHb 
results for non-diabetic, non-renal control patients are within the normal reference ranges 
given for GHb - see result and interpretation in section 3 6.4.2
Male non-diabetic renal patients on glucose have a mean GHb result of 4.6% +/-1.0 
when n = 28, and a mean random plasma glucose concentration of 5.0 +/- 1.1. Female non­
diabetic renal patients on glucose have a mean GHb of 4.9% +/- 1.1 when n = 15, and a 
mean random plasma glucose concentration of 5.8 +/- 2.1. The results of the non-diabetic 
renal patients on glucose are within the normal reference ranges given for the respective 
tests.
Male non-diabetic renal patients on icodextrin have a mean GHb result of 5.0% +/-
0.8 when n = 4, and a mean random plasma glucose concentration of 6.0 +/- 1.3. Female
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non-diabetic renal patients on icodextrin have a mean GHb result of 5.0% +/- 0.9 when n = 
5, and a mean random plasma glucose concentration of 6.0 +/- 2.8. The results of the non­
diabetic renal patients on icodextrin are within the normal reference ranges given for the 
respective tests.
Male controls (diabetic, non-renal patients) have a mean GHb result of 8.6 +/- 4.6 
when n = 20. Female controls have a mean GHb result of 8.8 +/- 4.7 when n = 20. As 
expected, these results show that GHb results for diabetic, non-renal control patients are 
above the normal reference ranges given for GHb.
Male diabetic renal patients on glucose have a mean GHb result of 8.9% +/- 7.0 
when n = 8, and a mean random plasma glucose concentration of 13.2 +/- 11.1. Female 
diabetic renal patients on glucose have a mean GHb result of 8.7% +/- 6.7 when n = 5, and 
a mean random plasma glucose concentration of 11 4 +/- 4.0. As expected the results of the 
diabetic renal patients on glucose are above the normal reference ranges given for the 
respective tests. The mean GHb results for this group of patients was not 'clinically' 
différent from results obtained from diabetic patients not being treated with CAPD.
Male diabetic renal patients on icodextrin have a mean GHb of 7.0% +/- 0 when n = 
2, and a mean random plasma glucose concentration of 8.0 +/- 0.8. There were no female 
diabetic renal patients on icodextrin. The results show that GHb results of the two male 
diabetic renal patients on icodextrin are within the normal reference ranges given for GHb, 
and the mean random plasma glucose concentration was above the normal reference range 
for the test. However, the findings of this particular experiment was limited as only two 
male diabetic renal patients on icodextrin were studied. More male diabetic renal patients on 
icodextrin need to be studied in order to get a better average and female diabetic renal 
patients on icodextrin must also be studied.
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Table 12 Clinical and laboratory data on the renal patients on CAPD treatment.
No.
(Gp.
No.)
Age Sex 
(years) M/F
Diabetes 
type and 
duration 
(years)
CAPD 
type and 
duration 
(months)
Urea 
mmol/1 
(réf. range 
3.3 -10.2)
Creatinine 
pmol/1 
(réf. range 
71 -152)
GHb
(%)
1(1) 71 M ND Glucose (26) 18.7 1178 4.9
2(5) 56 M NIDDM (15) Glucose (6) 16.0 358 8.7*
3(7) 38 M IDDM (25) Icodextrin (14) 19.0 241 7.0*
4(1) 71 M ND Glucose (15) 17.4 652 4.3
5(1) 41 M ND Glucose (19) 23.0 982 4.4
6(1) 70 M ND Glucose (17) 16.3 1031 5.1
7(2) 66 F ND Glucose (4) 10.7 789 5.5
8(2) 74 F ND Glucose (7) 23.1 608 5.4
9(2) 49 F ND Glucose (10) 18.9 1012 4.5
10(1) 71 M ND Glucose (4) 12.3 729 4.4
11 (1) 78 M ND Glucose (20) 18.0 809 5.4
12(1) 72 M ND Glucose (17) 22.2 1108 6.0
13(4) 68 F ND Icodextrin (4) 33.2 914 4,7
14(1) 70 M ND Glucose (72) 18.6 630 4.5
15(1) 56 M ND Glucose (16) 27.5 746 4.8
16 (1) 61 M ND Glucose (26) 17.4 997 4.8
17 (2) 76 F ND Glucose (5) 16.5 608 5.3
18(2) 74 F ND Glucose (50) 14.7 737 4.3
19(5) 37 M IDDM (19) Glucose (8) 23.1 622 16.6*
20(5) 71 M NIDDM (6) Glucose (27) 16.1 445 8.4*
21(4) 52 F ND Icodextrin (103) 9.5 855 5.4
22(2) 60 F ND Glucose (11) 14.7 981 4.4
23(1) 54 M ND Glucose (11) 19.2 901 4.1
24(1) 38 M ND Glucose (17) 22.9 1078 4.0
25(2) 79 F ND Glucose (10) 21.6 790 4.8
26(1) 74 M ND Glucose (22) 28.1 711 4.1
27(2) 57 F ND Glucose (8) 15.3 849 4.9
28(1) 69 M ND Glucose (15) 20.1 767 4.4
29 (2) 65 F ND Glucose (37) 3.7 65 5.8
30(3) 71 M ND Icodextrin (42) 23.3 855 4.5
31(2) 74 F ND Glucose (106) 20.4 716 4.6
32(2) 59 F ND Glucose (18) 14.3 1039 5.0
33(6) 59 F IDDM (16) Glucose (15) 21.7 680 13.7*
34(1) 79 M ND Glucose (11) 23.3 957 5.0
35(1) 62 M ND Glucose (13) 23.0 868 4.4
36(1) 52 M ND Glucose (39) 19.1 1060 3.6
37(1) 45 M ND Glucose (5) 21.9 703 4.1
38(2) 66 F ND Glucose (7) 13.4 720 4.9
39(2) 67 F ND Glucose (13) 6.4 422 4.4
40(4) 72 F ND Icodextrin (6) 21.8 694 5.0
41 (1) 55 M ND Glucose (17) 10.5 401 4.6
42(5) 42 M NIDDM (20) Glucose (13) 18.0 918 9.9*
43(3) 70 M ND Icodextrin (21) 22.6 1005 4.9
44(1) 80 M ND Glucose (11) 15.2 892 4.9
45(7) 72 M NIDDM (1) Icodextrin (25) 18.7 1131 7.0*
46(1) 73 M ND Glucose (5) 20.2 1054 4.5
47(1) 58 M ND Glucose (10) 21.9 823 4.2
48(2) 75 F ND Glucose (15) 11.0 804 5.5
49(5) 74 M NIDDM (1) Glucose (35) 15.5 901 8.0*
50(6) 71 F IDDM (15) Glucose (4) 8.1 374 8.1 *
51(1) 63 M ND Glucose (23) 15.6 985 4.7
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Table 12 cont.d Clinical and laboratory data on the renal patients on CAPD treatment.
No.
(Gp.
No.)
Age Sex 
(years) M/F
Diabetes 
type and 
duration 
(years)
CAPD 
type and 
duration 
(months)
Urea 
mmol/1 
(réf. range 
3.3-10.2)
Creatinine 
pmol/1 
(réf. range 
71 -152)
GHb
(%)
52(1) 51 M ND Glucose (23) 22.0 614 5.2
53(6) 56 F IDDM (29) Glucose (17) 11.0 480 4.4*
54(2) 67 F ND Glucose (35) 18.3 603 4.0
55(1) 57 M ND Glucose (16) 11.5 401 4.4
56(4) 78 F ND Icodextrin (9) 12.8 680 5.4
57(4) 78 F ND Icodextrin (31) 19.6 1119 4.3
58(1) 77 M ND Glucose (19) 22.6 941 4.7
59(5) 49 M IDDM (39) Glucose (6) 21.6 788 8.7*
60(6) 46 F NIDDM (11) Glucose (37) 20.0 655 7.8*
61(6) 54 F IDDM (12) Glucose (5) 17.3 588 9.3*
62 (5) 60 M IDDM (10) Glucose (4) 24.9 954 5.8*
63(1) 77 M ND Glucose (27) 179 982 3.8
64(1) 84 M ND Glucose (16) 11.9 709 4.9
65(5) 77 M NIDDM (1) Glucose (47) 15.3 489 5.2*
66(3) 55 M ND Icodextrin (10) 30.1 869 5.4
67(3) 81 M ND Icodextrin (23) 20.6 601 5.2
ND = 
IDDM = 
NIDDM: 
*
non-diabetic
insulin-dependent diabetes mellitus 
non-insulin-dependent diabetes mellitus 
denotes patients with diabetes mellitus
Gp. No = Group number
Patients were put into 8 groups for statistical analysis (see Table 16):
1 =  
2 =
3 =
4 =
5 =
6 =
7 =
8 =
male non-diabetic on glucose 
female non-diabetic on glucose 
male non-diabetic on icodextrin 
female non-diabetic on icodextrin 
male diabetic on glucose 
female diabetic on glucose 
male diabetic on icodextrin 
female diabetic on icodextrin
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Table 13 Laboratory data on controls (non-diabetic, non-renal patients).
No. Age Sex 
(years) M/F
Urea 
mmol/1 
(réf. range 
3.3 -10.2)
Creatinine 
nmol/1 
(réf. range 
71 -152)
GHb
(%)
1 63 M 4.2 103 5.1
2 69 M 6.0 108 5.1
3 80 M 4.5 63 4.7
4 59 M 5.7 85 3.7
5 80 M 8.9 88 4.4
6 89 M 9.5 124 6.8
7 82 M 4.6 70 5.8
8 81 M 5.4 79 4.6
9 66 M 3.7 84 6.8
10 83 M 5.9 83 4.6
11 86 M 4.8 79 4.2
12 64 M 6.4 95 5.0
13 66 M 5.1 102 4.2
14 84 M 7.9 78 4.7
15 67 M 9.4 89 4.7
16 78 M 8.2 116 6.7
17 84 M 6.1 113 4.1
18 63 M 3.7 122 4.5
19 81 M 6.3 70 7.5
20 41 M 4.0 71 3.2
21 25 M 3.0 89 3.5
22 62 M 7.1 83 3.7
23 73 M 5.3 99 5.5
24 70 M 3.7 74 5.1
25 36 M 3.7 86 3.5
26 51 M 5.0 96 3.7
27 66 M 3.8 77 6.2
28 81 M 7.0 120 4.6
29 59 M 3.9 80 6.9
30 94 M 3.5 71 4.8
31 81 M 4.8 105 6.6
32 65 M 5.0 100 4.3
33 79 M 4.7 93 4.3
34 65 M 4.0 89 4.0
35 67 M 7.3 108 4.1
36 56 M 6.2 117 3.8
37 84 M 6.1 97 3.8
38 41 M 4.8 108 4.1
39 83 M 5.1 86 4.4
40 84 M 3.4 86 4.6
41 93 F 9.7 115 6.9
42 88 F 6.0 99 4.5
43 85 F 5.5 73 5.1
44 88 F 3.7 57 3.8
45 95 F 6.1 94 5.0
46 73 F 3.0 70 4.8
47 32 F 2.5 70 4.0
48 88 F 5.8 80 5.4
49 43 F 40 74 3.7
50 73 F 5.5 76 4.8
51 90 F 5.3 90 3.8
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Table 13 cont.d Laboratory data on controls ( non-diabetic, non-renal patients).
No. Age Sex 
(years) M/F
Urea 
mmol/1 
(réf. range 
3.3 -10.2)
Creatinine 
pmol/1 
(réf. range 
71 -152)
GHb
(%)
52 83 F 3.7 55 4.1
53 87 F 8.5 57 4.2
54 81 F 6.2 77 4.6
55 78 F 3.8 58 4.1
56 80 F 6.5 56 3.7
57 56 F 4.3 51 3.8
58 78 F 3.3 86 4.5
59 87 F 9.1 81 5.4
60 97 F 4.6 69 4.0
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Table 14 Laboratory data on controls (diabetic, non-renal patients).
No. Age Sex 
(years) M/F
Diabetes
IDDM/
NIDDM
Urea 
mmol/1 
(réf. range 
3.3 -10.2)
Creatinine 
pmol/l 
(réf. range 
71 -152)
GHb
(%)
1 76 M NIDDM 3.7 76 6.2
2 46 M IDDM 4.5 88 10.8
3 25 M IDDM 3.9 76 5.9
4 35 M NIDDM 5.1 91 6.3
5 71 M IDDM 8.6 133 10.6
6 69 M NIDDM 6.2 114 10.2
7 63 M NIDDM 6.1 78 7.9
8 73 M NIDDM 5.6 94 7.3
9 61 M NIDDM 5.5 76 9.2
10 62 M NIDDM 9.9 117 8.7
11 71 M NIDDM 4.8 77 8.2
12 64 M NIDDM 4.7 116 6.2
13 46 M NIDDM 5.4 85 10.9
14 70 M NIDDM 5.3 117 8.3
15 59 M NIDDM 5.3 95 8.5
16 61 M NIDDM 8.9 134 5.6
17 68 M NIDDM 4.3 87 8.5
18 64 M NIDDM 4.0 93 7.3
19 66 M IDDM 4.6 98 15.3
20 60 M NIDDM 4.5 81 10.0
21 73 F NIDDM 5.0 72 8.8
22 34 F IDDM 4.1 80 12.1
23 68 F IDDM 4.3 77 10.1
24 71 F NIDDM 8.1 83 6.8
25 69 F IDDM 4.8 66 13.9
26 78 F NIDDM 7.6 67 11.6
27 86 F NIDDM 5.6 92 5.3
28 88 F NIDDM 2.8 65 9.5
29 53 F IDDM 3.6 70 10.7
30 55 F NIDDM 3.8 65 5.1
31 76 F IDDM 5.8 58 7.5
32 37 F IDDM 3.8 71 9.4
33 67 F IDDM 6.6 79 9.8
34 71 F NIDDM 6.3 76 10.0
35 52 F NIDDM 6.4 67 7.9
36 41 F IDDM 4.8 98 5.4
37 60 F NIDDM 5.3 60 6.8
38 62 F IDDM 3.5 73 9.0
39 71 F NIDDM 3.3 68 9.0
40 88 F NIDDM 5.1 64 7.2
IDDM = insulin-dependent diabetes mellitus
NIDDM = non-insulin-dependent diabetes mellitus
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Table 15 Random plasma, glucose concentrations (mmol/1) on rénal patients on CAPD
treatment.
No. 1 2 3 4 5 6 7 8 9  10 Mean
(Gp. (Most recent) Monthly plasma glucose concentrations (mmol/1) (Least recent) +/-2SD
No.) ref. range 3.6 - 6.1 mmol/1
1(1) 5.6 4.9 5.0 3.9 5.6 . 4.6 5.7 5.0 3.9 5.6 5.0
+/-1.36
2(5) 6.1 20.4 22.8 12.6 13.9 13.0 7.2 19.4 10.8 8.5 13.5*
+/-11.5
3(7) 4.5 5.4 11.0 6.6 6.5 4.0 7.3 8.7 11.2 11.9 7.7* 
+/- 5.7
4(1) 5.4 5.7 6.3 3.3 4.2 3.9 4.0 3.6 4.2 5.1 4.6
+/- 2.0
5(1) 5.6 6.2 4.9 4.6 5.2 5.6 3.9 4.7 4.6 3.8 4.9
+/-1.5
6(1) 6.1 4.3 7.4 4.4 6.2 3.8 5.4 
+/- 2.8
7(2) 6.4 6.5 5.5 5.0 4.4 5.8 6.0 5.3 5.3 7.1 5.7 
+/-1.6
8(2) 5.8 5.4 5.0 4.8 3.9 5.0
+/-1.4
9(2) 4.6 5.2 6.7 4.9 10.4 4.7 4.4 4.4 4.6 5.5
+Z-3.9
10 (1) 5.6 7.3 6.0 5.4 6.2 8.5 4.8 7.6 5.0 7.1 6.4
+/- 2.4
11(1) 5.0 4.4 5.2 4.5 3.7 3.9 3.9 4.4
+/-1.2
12(1) 5.4 4.1 9.5 4.1 5.8
+/-5.1
13(4) 4.9 6.2 6.3 5.7 5.1 5.4 5.8 5.6 
+/-1.1
14 (1) 5.5 4.5 5.7 4.9 4.5 4.8 6.7 5.0 4.8 5.2
+/-1.4
15 (1) 7.3 4.7 5.9 4.8 3.7 5.0 5.0 4.7 5.1
+/-2.1
16 (1) 5.1 4.5 5.1 5.3 6.4 4.2 5.2 3.6 4.7 3.3 4.7
+/-1.8
17(2) 8.0 8.6 8.8 9.0 7.3 8.3
+/-1.4
18(2) 4.4 5.5 6.6 5.5 
+/- 2.2
19 (5) 28.4 20.2 39.8 22.1 17.0 25.5* 
+/-18.0
20(5) 12.6 14.1 24.4 10.9 8.8 10.5 6.8 19.0 14.7 8.5 13.0* 
+/-10.7
21(4) 5.7 4.2 4.4 4.8
+/-1.6
22(2) 6.7 5.4 4.9 7.8 7.9 6.5
+/- 2.7
23(1) 3.3 3.6 3.5 4.2 6.2 4.2
+/- 2.4
24(1) 5.4 5.4 7.1 6.5 5.9 5.2 7.2 5.9 5.2 5.3 5.9
+/-1.5
25(2) 4.9 6.2 5.3 4.8 6.2 5.3 4.1 5.4 5.2 4.6 5.2
+/-1.3
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Table 15 cont.d Random plasma glucose concentrations (mmol/1) on renal patients on
CAPD treatment.
No. 1 2 3 4 5 6 7 8 9 10 Mean
(Gp. (Most recent) Monthly plasma glucose concentrations (mmol/1) (Least recent) +/-2SD
No.) réf. range 3.6 - 6.1 mmol/1
26(1) 6.1 6.4 4.5 4.7 5.2 5.3 3.9 5.2 4.4 4.8 5.1
+/-1.5
27(2) 5.3 5.9 4.7 5.3 
+/-1.2
28(1) 6.3 4.8 4.3 7.0 5.9 4.9 4.9 5.1 4.9 5.3
+/-1.7
29(2) 10.0 5.9 5.9 5.8 5.7 6.3 6.2 6.1 5.4 6.4 6.4
+/- 2.6
30(3) 5.2 4.2 6.0 4.9 4.1 5.0 7.2 4.9 5.1 8.6 5.5 
+/- 2.8
31(2) 5.3 5.8 5.0 6.2 5.0 6.4 6.5 5.7
+/-1.3
32(2) 4.3 4.6 4.0 4.3 5.8 4.4 3.7 5 1 5,0 4.7 4,6 
+/-1.2
33(6) 6.1 17.9 19.3 13.0 13.5 14.0 14.0*
+/- 9.3
34(1) 5.1 5.5 4.0 4.0 4.5 3.7 3.7 3.7 4.0 4.6 4.3
+/-1.3
35(1) 5.4 8.8 4.1 5.7 5.1 6.2 4.3 6.5 5.8
+/- 3.0
36(1) 5.0 3.6 4.5 4.4 5.4 2.7 3.7 3.1 4.1 4.7 4.1
+/-1.7
37(1) 6.3 7.0 4.3 4.3 4.1 4.6 4.8 6.1 5.2
+1-2.2
38(2) 6.2 5.2 5.5 4.8 6.0 4.2 3.6 4.0 5.2 3.1 4.8
+/- 2.1
39(2) 11.0 7.3 7.6 9.8 13.1 5.9 5.7 7.3 6.0 5.7 7.9
+/-5.1
40(4) 6.4 6.3 8.0 10.5 8.8 8.0
+/- 3.5
41 (1) 6.9 4.9 5.3 4.3 5.1 5.6 5.5 5.9 5.4
+/-1.5
42 (5) 9.0 3.6 9.9 5.5 7.0* 
+/- 5.9
43(3) 4.6 5.8 6.3 6.7 6.3 5.1 4.7 4.7 4.5 4.6 5.3
+/-1.7
44(1) 4.7 4.5 4.7 4.1 4.5 6.2 5.1 4.8
+/-1.4
45(7) 7.6 6.9 12.3 8.1 9.8 7.5 7.8 7.9 8.2 6.5 8.3* 
+/- 3.3
46(1) 3.8 5.1 5.1 5.1 4.2 4.9 4.7
+/-1.1
47(1) 3.6 4.5 4.0 4.3 4.8 4.2
+/-0.9
48(2) 5.1 4 9 45 75 4.9 6.5 4.9 4,4 5.1 5.4 5.3
+/-1.9
49(5) 16.0 15.8 23.7 28.4 10.2 5.6 6.9 4.8 6.2 4.0 12.2* 
+/-17.1
50(6) 9.5 6.8 5.4 7.7 11.3 10.7 108 24,9 5.1 6.4 9,9*
+/-11.5
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Table 15 cont.d Random plasma glucose concentrations (mmol/1) on renal patients on
CAPD treatment.
No. 1 2 3 4 5 6 7 8 9 10 Mean
(Gp. (Most recent) Monthly plasma glucose concentrations (mmol/1) (Least recent) +/-2SD
No.) ref. range 3.6 - 6.1 mmol/1
51 (1) 4.8 4.7 4.8 4.2 4.4 4.0 4.3 5.4 7.5 3.8 4.7+/- 2.1
52(1) 4.0 5.4 6.2 4.5 3.6 5.5 4.5 4.4 4.2 5.1 4.7
+/-1.6
53(6) 4.2 4.5 18.3 4.1 7.6 24.3 5.8 5.2 9.8 7.3 9.1*
+/-13.6
54(2) 5.9 5.6 4.6 5.1 5.9 5.2 4.8 5.0 5.0 4.6 5.2
+/-1.0
55 (1) 5.7 5.6 6.2 6.5 5.1 4.3 6.1 4.8 5.5+/-1.5
56(4) 6.0 5.3 6.4 5.7 5.1 7.7 111 6.8
+/- 4.2
57(4) 5.0 5.5 4.8 5.1 6.3 4.3 4.7 4.1 36 4.4 4.8
+/-1.5
58(1) 4.9 4.9 4.0 5.4 4.2 5.5 4.8+/-1.2
59(5) 5.9 11.3 5.1 3.6 23.5 15.3 34.0 14.7 6.3 18.3 13.8*
+/-19.2
60(6) 12.4 13.3 7.8 15.3 9.2 8.3 11.3 14.3 15.1 6.3 11.3*+/- 6.5
61(6) 8.4 15.7 14.0 12.7*
+/- 7.6
62 (5) 8.4 8.0 10.9 10.4 5.0 6.0 8.1*+/- 4.7
63(1) 5.9 4.7 4.7 5.0 6.0 5.3 5.6 7.0 6.4 4.5 5.5 
+/-1.6
64(1) 8.6 6.8 5.1 4.5 4.8 5.0 4.6 5.3 4.6 5.3 5.5+/- 2.6
65 (5) 111 14.3 14.0 12.0 14.8 17.5 9.4 15.2 9.8 9.6 12.8*+/- 5.6
66(3) 7.7 5.3 6.9 10.7 6.0 6.9 5.6 6.1 4.4 5.9 6.6+/- 3.5
67 (3) 8.1 5.8 6.1 8.9 6.6 5.5 4.3 5.4 6.5 6.5 6.4+/- 2.7
* denotes patients with diabetes mellitus
Gp. No = Group number
Patients were put into 8 groups for statistical analysis (see Table 16):-
1 = male non-diabetic on glucose
2 = female non-diabetic on glucose
3 = male non-diabetic on icodextrin
4 = female non-diabetic on icodextrin
5 = male diabetic on glucose
6 — female diabetic on glucose
7 = male diabetic on icodextrin
8 ■ female diabetic on icodextrin
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Table 16 Summary of results (mean +/- 2SD) on renal patients on CAPD treatment and 
control patients.
(Gp. No.)
Sex (M/F) 
(D/ND) 
Osmotic agent
No. Age CAPD 
(years) duration 
(months)
Urea Creatinine 
mmol/1 mmol/1 
(ref range (ref range 
3.3-10.2) 71-152)
GHb
(%)
Random monthly 
plasma glucose 
concentration 
(ref range 
3.6 - 6.1 mmol/1)
(1) M/ND 
glucose
28 65
+/-26
20
+Z-26
19 1 
+/- 8.9
852
+/- 397
4.6 
+/- 1.0
5.0 
+/- 1.1
(2) F/ND 
glucose
15 66
+/-19
23
+/- 52
15.2 
+/- 10.7
712 
+/- 476
4.9
+/-1.1
5.8
+/-2.1
(3) M/ND 
icodextrin
4 69
+/-21
24
+/- 27
24.2 
+/- 8.3
833
+/- 337
5.0 
+/- 0.8
6.0
+/- 1.3
(4) F/ND 
icodextrin
5 70
+/-21
31
+/- 84
19.4 
+/- 18.4
852
+/-360
5.0
+/- 0.9
6.0
+A 2.8
(5) M/D 
glucose
8 56
+/- 29
16
+/- 32
19.3 
+/- 7.7
653
+/- 474
8.9
+/-7.0
13.2 
+/- 11.1
(6) F/D 
glucose
5 60
+/-15
10
+/-13
14.5 
+/- 12.3
531
+/- 265
8.7
+Z-6.7
11.4
+/-4.0
(7) M/D 
icodextrin
2 55
+/- 48
20 
+/- 16
18.9
+/-0.4
686
+/- 1258
7.0 
+/- 0
8.0 
+/- 0.8
(8) F/D 
icodextrin
0
~
M/ND
control
N/A
40 70
+/-31
N/A 54
+/- 3.4
92
+/- 32
4.8
+A2.2
F/ND
control
N/A
20 79
+/- 34
N/A 5.4
+/-4.0
74
+/- 33
4.5 
+/- 1.6
M/D
control
N/A
20 61
+A26
N/A 5.5
+/- 3.4
96
+/-40
8.6
+/- 4.6
F/D
control
N/A
20 65
+/- 32
N/A 5.0
+/- 2.9
73
+/-20
8.8
+/- 4.7
M = male 
F = female
ND = 
D =
non-diabetic
diabetic
N/A = not applicable
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6.0 DISCUSSION
6.1 Effect of Haemoglobin Concentration on GHb Results
The measurement of GHb by the GHb-100 analyser from Drew Scientific appears to 
be relatively independent of the haemoglobin concentration. The GHb-100 analyser 
measures total glycohaemoglobin by boronate affinity chromatography and the results are 
expressed as a ratio and not in absolute terms. It can be seen from Table 7 that the PCV of 
30% to 70% shows a very small increasing trend in GHb results (0.3% GHb). A PCV of 
30% gives a GHb of 8.7%, while a PCV of 70% gives a GHb of 9.0%.
6.2 Effect of Using 1% Triton X-100 as a Haemolysing Reagent
The results obtained for the study of the effect of using 1% Triton X-100 as a 
haemolysing reagent is shown in Figure 4. It can be seen from Figure 4 that Triton X-100 
should not be used as a haemolysing reagent for the GHb-100 analyser as it causes 
irreversible damage to the column, thus preventing the effective separation and 
measurement of GHb. The use of 1% Triton as a haemolysing reagent was discontinued 
after the results of its affect were known. Drew Scientific were informed of our results of 
the effects of using Triton X-100 as a haemolysing reagent. They repeated our experiment
and confirmed our results.
Deionised water (Figure 3) does not interfere with or adversely affect the GHb 
separation on the GHb-100 analyser. We agree with Drew Scientifics recommendation of 
using deionised water as the haemolysing reagent for the GHb-100 analyser.
6.3 Packed Cells versus Whole Blood
The results of the study of packed cells versus whole blood is shown in Figure 5. It
can be seen from Figure 5 that there is a very good correlation between the GHb results
from packed cells and those from whole blood, n = 40, y = 0.9572x - 0.0987 where y =
whole blood GHb (%) x = packed cells GHb (%), r = 0.9904.
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Drew Scientific recommend 10 microlitres of whole blood to be haemolysed with 1 
ml of deionised water. This study showed that 10 microlitres of packed cells can be 
haemolysed with 2 ml of deionised water to obtain similar readings. Our laboratory now 
uses packed cells for the preparation of haemolysates for the measurement of GHb on the 
GHb-100 analyser, as we find the use of packed cells easier and more convenient than 
whole blood.
6.4 Precision-nm Study
The results of the precision-run are shown in Tables 8 and 9. It can be seen 
from Tables 8 and 9 that the GHb-100 analyser is a very precise instrument for the 
measurement of GHb. The calculated % CV for the low GHb precision-run (mean = 
5.7125) was 1.74% when n = 40. The calculated % CV for the high GHb precision-run
(mean = 10.885) was 1.76% when n = 53.
The Pierce method of measuring GHb is reported to have à coefficient of variation
of about 2% for replicate estimations done on normal and diabetic patients (166). Our
results show that the % CV obtained for the precision-run study on the GHb-100 analyser 
are within the recommendations of the National Institute of Health Diabetes Group Expert 
Committee on Glycosylated Haemoglobin which suggest an intra assay CV of 5% (171), 
and are an improvement to the Pierce method.
6.5 Between-batch Precision Study
The results obtained for the between-batch precision study is shown in Table 10. It 
can be seen from Table 10 that the between-batch precision for the GHb-100 analyser is 
very good.
The results of the in-house low and high controls were as follows:-
In-house low control n = 89 mean = 6.3697 % CV = 4.69
In-house high control n = 89 mean = 9.6831 % CV = 3.39
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The Pierce method of measuring GHb is reported to have a between-batch 
coefficient of variation of about 5-6% (167). Our results show that the % CV obtained for 
the between-batch precision study are within the recommendations of The National Institute 
of Health Diabetes Group Expert Committee on Glycosylated Haemoglobin which suggest 
an inter assay CV of 5% (171) and are an improvement to the Pierce method.
By comparison with published precision studies on other methods for determining 
GHb (Table 6) the Drew GHb-100 method is in the most precise group, comparing 
favourably with other fully automated chromatography systems.
6.6 Correlation Study
The best correlation of GHb results between the Pierce and Drew method was 
obtained for the correlation study of assigned calibrant values of BRI = 3.8% BR2 = 
10.0%. The results are shown in Figures 8 and 9. It can be seen from these figures that 
the correlation of Pierce and Drew GHb results was very good, n = 50, y = 1.018x - 
0.1034 where y = Drew GHb (%) x = Pierce GHb (%), r = 0.9806, p = <0.0001. The 
percentage difference of GHb results between the Pierce and Drew methods showed no 
overall positive or negative bias.
The mean difference of GHb results (%) between the methods (Drew-Pierce) = 0.0440.
The mean percentage difference of GHb results (%) between the methods (Drew-Pierce/ 
Pierce x 100) = 0.432.
For a brief period our laboratory calibrated the GHb-100 analyser using the 
assigned calibrant values of BRI = 3.8% BR2 = 10.0%. The advantage of using this 
calibrant value was that it allowed us to use the reference range given for the Pierce 
method, therefore causing no disruption to our existing system of reporting GHb results - 
hence making the change in analytical method invisible to the requesting clinician.
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Biorad versus Primus Calibrants
The GHb-100 analyser was calibrated using the assigned calibration value BRI = 
3.8%, BR2 = 10.0%. Primus 1 and 2 were then analysed as samples four times each. The 
mean GHb result for Primus 1 = 5.2%, the mean GHb result for Primus 2 = 14.8%.
DCCT values for glycohaemoglobin are derived from assay by ion-exchange 
chromatography and consequently give different results from affinity methods. Figures 10 
and 11 show the difference. The correlation of GHb results obtained for the calibrant values 
BRI = 3.8%, BR2 = 10.0% versus Primus 1 = 5.8%, Primus 2 = 13.3% (DCCT values) 
was n = 139, y = 0.7585x + 2.0154 where y = Primus GHb (%) x = Biorad GHb (%), r =
0.9981, p “  <0.0001. An intercept and slope change caused the percentage difference of 
GHb results between Biorad and Primus calibrants to show a positive bias for low GHb 
values and a negative bias for high GHb values relative to the affinity method. The DCCT 
HbAlc values were established on a first generation ion-exchange analyser (Biorad, 
Diamat), and it is now known that carbamylated and acetylated Hb co-eluted with the 
HbAlc peak. This probably accounts for the intercept shown on Figure 10.
The diabetes control and complications trial (DCCT) (173), demonstrated that 
development and progression of the chronic complications of diabetes are related to the 
degree of altered glycaemia as determined by determinations of glycohaemoglobin. Thus, 
the use of glycohaemoglobin testing for routine diabetes care provides an objective measure 
of a patients risk for developing diabetic complications. Results of this test alert patients and 
health providers to the need for change in the treatment plan. Optimal use of 
glycohaemoglobin testing for diabetes care would benefit from universal standardisation of 
the test results.
Standardisation of test results to DCCT numbers would be particularly attractive 
given that the DCCT GHb values predict the risk of diabetic complications. In addition, 
data from the DCCT were used to establish a relationship between GHb value and the mean
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blood glucose concentration, a task that would be extremely difficult for most laboratories
to do independently for each method.
There is now a greatly increased need for accurate and precise assays that reflect 
blood glucose concentrations integrated over time. Although glycohaemoglobin is an 
excellent measure of average glycaemia, as already mentioned, clinical laboratories employ 
many diverse methods to quantify it. Some methods are labour-intensive, slow, relatively 
expensive, and imprecise. Furthermore, most assays are not well standardised (177-179), 
such that results from one laboratory are not easily interchangeable with those from 
another. Therapeutic alterations based on such technical discrepancies may place patients in 
intensive treatment regimes at significant risk of life-threatening hypoglycaemia
Recent research clearly shows that calibration and standardisation results in better 
long-term precision, decreases lot-to-lot variability, and improves interassay precision - as 
well as allowing direct comparison of data produced by the various methods (177-179)
All the major manufacturers of GHb and HbAlc analysers have recently 
recommended calibrating their instruments using DCCT referenced standards. Many U.K. 
hospital laboratories have now adopted this approach.
Our method of calibration, referenced to the Pierce method, gives us intra- 
laboratory consistency, but the trend is continuing towards DCCT calibrants. We have now 
also decided to change in this direction. This has necessitated changes to our existing 
reference ranges - see Table 11, but in the long-run patient management will benefit from
better inter-laboratory agreement.
6.7 Column Life of the GHb-100 Analyser
The results of the study of extending the column life of the GHb-100 analyser 
showed that a maximum of 720 samples can be processed with one column. However, we 
found that the practice of exceeding Drew Scientifics recommendation of 500 samples
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should not be encouraged as the precision and separation of GHb deteriorates with the over 
use of the column.
Some competing ion-exchange chromatography systems have a maximum column 
life of 150 tests. The 500 tests per column offered by the GHb-100 analyser is an important 
advantage and should result in lower running costs.
6.8 Problems Encountered with the GHb-100 Analyser when in Routine 
Use
When the GHb-100 analyser was used routinely in our laboratory, after several 
months use, a shifting baseline was found to give falsely elevated GHb results. Figures 15 
and 16 show the shifting baseline of the low and high carryover samples respectively. A low 
carryover of 6.5% was found to give a GHb result of 7.1%, and a high GHb carryover of 
9.5% was found to give a GHb result of 10.3%.
Drew Scientific were informed about our findings and they have now changed their 
software program to prevent the baseline from shifting.
6.9 Improvements to the GHb-100 Analyser - Barcode Reading and 
Download Facilities
The GHb-100 analyser has a facility for reading bar coded patient samples using a 
light pen attached to a special keyboard. The data is read directly into the sample 
identification field and printed on the results sheet and summary sheets. The GHb-100 
analyser also has a facility to send a summary of the results to another computer, for 
example, a central laboratory computer.
The GHb-100 analyser accumulates a summary of the results for each sample in a 
batch. It can output this summary list via the RS232 serial port on the rear of the 
instrument. Checksum characters are added to the results so that the laboratory can check 
there have been no errors in transmission. This facility is included as standard, though it may
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have to be tailored to suit the requirements of our laboratory. The system hardware is fitted 
as standard (169).
The use of the barcode reading and downloading facilities will ease and quicken 
reporting of our GHb results. In addition it would reduce sample identification and 
transcription errors, therefore greatly improving the standard and service of our GHb 
measurements.
6.10 Renal Patients on CAPD Treatment
Glucose intolerance is common in uraemic patients and is mainly due to an impaired 
peripheral sensitivity to the action of insulin One potential hazard with CAPD is that the 
peritoneal glucose load could lead to a depletion of the pancreatic beta-cells. This could 
create a diabetic state, which would add to the already impaired glucose tolerance in 
uraemia (180).
Lameire et al. (1) studied the long-term effects of CAPD treatment on carbohydrate 
and lipid metabolism. They concluded that the long-term follow-up of CAPD patients 
indicated that these patients were at relatively low risk of developing de novo diabetes 
mellitus. Transperitoneal glucose absorption and the blood glucose and serum insulin 
response to the glucose load remained relatively unchanged with time.
Smith et al. (181) determined glycohaemoglobin and carbamylated haemoglobin in 
patients with uraemia and/or diabetes mellitus. Glycohaemoglobin measured by ion- 
exchange chromatography (HbAj, HbAjc, HbAj a + fc) was elevated in non-diabetic 
patients, while colorimetrically determined glycohaemoglobin was similar to controls. 
Patients with diabetes mellitus and normal renal function had similar glycohaemoglobin 
concentrations to those with renal failure, in patients with diabetes mellitus. Both methods 
showed an excellent correlation, independent of renal function, in patients with diabetes 
mellitus. The HbAjc component was more influenced by diabetes and the HbAj a + b
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component was relatively more dependent on renal function. Carbamylated haemoglobin 
was detected in all subjects, but was grossly elevated in uraemia. Carbamylated 
haemoglobin significantly correlated with renal function and chromatographically 
determined glycohaemoglobin. Data from this study strongly suggested that the apparent 
elevation of chromatographically determined glycohaemoglobin in uraemia was due to the 
increased formation of carbamylated haemoglobin. However, in patients with diabetes 
mellitus, independent of renal function, both the chromatographic and colorimetric methods 
of determining glycohaemoglobin were equally valuable and reliable.
Tzamaloukas et al. (182) measured glycohaemoglobin concentrations by affinity 
chromatography in the blood of 43 diabetic and non-diabetic patients on long term dialysis 
therapy (CAPD and haemodialysis) to determine the usefulness of this method of estimating 
glycaemic control in diabetic persons on dialysis therapy. In non-diabetic patients, 
glycohaemoglobin concentrations were within their normal reference range (4.0%-6.8%) 
for both continuous ambulatory peritoneal dialysis and haemodialysis.
Morgan et al. (183) measured glycohaemoglobin by affinity chromatography in 91 
non-diabetic subjects with chronic renal failure (25 on CAPD, 22 on haemodialysis, and 22 
on renal transplantation). Results were compared with those in a control group of 43 non­
diabetic subjects with normal renal function. Mean glycohaemoglobin measured by affinity 
chromatography was not significantly different from controls in any of the groups with 
chronic renal failure. They concluded that glycohaemoglobin measured by affinity 
chromatography appears to be unaffected by chronic renal failure.
The summary of my results of CAPD treatment on GHb concentration are shown in 
Table 16. Male non-diabetic, non-renal control patients had a mean GHb result of 4.8% +/- 
2.2 (+/- 2SD) when n = 40. Female non-diabetic, non-renal control patients had a mean 
GHb result of 4.5% +/-1.6 when n = 20. As expected the mean GHb results of non-diabetic 
non-renal control patients were within the normal reference.
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Male non-diabetic renal patients on glucose containing CAPD fluid had a mean GHb 
result of 4.6% +/- 1.0 (n = 28). Female non-diabetic renal patients on glucose containing 
CAPD fluid had a mean GHb result of 4.9% +/- 1.1 (n = 15). These results were within the 
normal reference range.
Lindholm et al. (12) did not indicate any change in the beta-cell response after 4 
months on CAPD. Their results were in accordance with those of Baeyer et al. (14), but in 
another study by Armstrong et al. (184) a further deterioration in glucose tolerance as well 
as a decreased rate of insulin secretion was observed.
There are few reports concerning the effects of dialysate glucose load on plasma 
glucose and insulin levels in CAPD patients. Armstrong et al. (185) have studied the effects 
of an exchange with 1.5% and 4.25% dialysate, respectively, and they found that plasma 
glucose and insulin levels increased above basal values only in the case of the 4.25% 
solutions. The authors concluded that if the use of hypertonic solutions is restricted there 
will be no continual stimulations of the pancreatic beta-cells due to the dialysate glucose 
alone during CAPD. De Santo et al. (17) and Splendiam et al. (16) found similar results, 
and also that glucagon levels decrease during a dwell with the 4.25% solution.
Short-term treatment with CAPD does not seem to lead to any further disturbances 
of the already abnormal glucose metabolism, but the long-term effects are yet unknown. 
The absorption of large quantities of glucose from glucose containing peritoneal fluids may 
contribute to hyperlipidaemia and obesity. Hypercholesterolaemia is a risk factor that may 
lead to the development of atherosclerosis.
Male non-diabetic renal patients on icodextrin had a mean GHb result of 5.0% +/- 
0,8 (n = 4), Female non-diabetic renal patients on icodextrin had a mean GHb result of 
5.0% +/- 0.9 (n = 5). These results were within the normal reference range.
Male diabetic non-renal control patients had a mean GHb result of 8.6% +/- 4.6 (n =
20). Female diabetic non-renal control patients had a mean GHb result of 8.8% +/- 4.7. As
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expected these results were above the normal reference range.
Male diabetic renal patients on glucose containing CAPD fluid had a mean GHb 
result of 8.9% +/- 7.0 (n = 8). Female diabetic renal patients on glucose containing CAPD 
fluid had a mean GHb result of 8.7% +/- 6.7 (n = 5). As expected these results were above 
the normal reference range. It is not surprising that the diabetic renal patients with 
hyperglycaemia and poor glycaemic control have a higher than normal GHb result. The 
authors of the MID AS study (34) suggested the use of icodextrin for CAPD treatment on 
diabetic renal patients as it leads to less carbohydrate absorption, and the small group of 
diabetic renal patients in the MED AS trial did perform well.
Table 12 shows the clinical and laboratory data on the renal patients on CAPD 
treatment. Patient no. 19, a male diabetic renal patient on glucose containing CAPD fluid, 
had a GHb result of 16.6%, and patient no. 33, a female diabetic renal patient on glucose 
containing CAPD fluid, had a GHb result of 13.7%. Table 15 shows the individual and 
mean (+/- 2SD) results of the random plasma glucose concentrations. These two patients 
who have very high GHb concentrations and extremely poor diabetic control have now been 
put on icodextrin by the physician of the renal ward to help improve their glycaemic control 
and normalise their GHb result.
Male diabetic renal patients on icodextrin had a mean GHb result of 7.0% +/- 0 (n = 
2). Unfortunately there were no female diabetic renal patients on icodextrin in the renal 
ward at the time of the study to evaluate for this project. The results of the male diabetic 
renal patients on icodextrin were within the normal reference range. The results of this 
particular experimentation were therefore limited, as only two male diabetic renal patients 
on icodextrin were studied, More diabetic renal patients on icodextrin must be studied and 
female diabetic renal patients on icodextrin must be studied in order to get a better average 
GHb result to determine the effect of icodextrin in these patients.
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7.0 CONCLUSION
The new Drew Scientific GHb-100 analyser has proved to be a rapid and precise 
instrument with a within-batch and between-batch precision of less than 5% CV. Whole 
blood or packed cells may be analysed, and small sample volumes are required (10 
microlitres). Each sample takes approximately 4 minutes to complete with a maximum of 99 
samples per batch and 1 space for an urgent sample. The GHb-100 analyser uses the 
boronate affinity low pressure liquid chromatography technique for the measurement of 
glycohaemoglobin. The boronate affinity method for measuring total glycohaemoglobin is 
not affected by the labile Schiff base, or abnormal haemoglobins. The methodology is not 
significantly affected by the haemoglobin concentration, and the temperature is controlled 
by the GHb-100 analysers internal computer at 50°C, so rigorous external temperature 
control by the laboratory worker is not required. During the trial period the use of the GHb- 
100 analyser has provided Brighton Health Care NHS Trust with a good quality and timely 
service for the measurement of GHb.
GHb is now a well recognised tool in helping to monitor the long-term treatment of 
diabetic patients. Consistently raised concentrations of GHb are associated with vascular 
damage attributed to formation of advanced glycation end products. Because 
hyperglycaemia has been reported in CAPD patients, I thought it would be interesting to 
study GHb in this group of patients.
The 67 patients studied were not selected in any conscious way and represented a 
typical cross-section of CAPD patients. There was no significant 'clinical' difference 
between the non-diabetic CAPD group and the control group. This could mean that the non 
diabetic patients on CAPD are not at risk from repeated exposure to high peritoneal cavity 
glucose concentrations or that GHb is not, in this case, an appropriate indicator of risk.
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APPENDIX
Table 1 Correlation between GHb results determined from packed cells and from whole 
blood
Table 2 Correlation study of assigned calibrant values of BRI = 4,3% BR2 = 11,3%
Table 3 Correlation study of assigned calibrant values of BRI = 3,8% BR2 = 10,0%
Table 4 Correlation study of Biorad versus Primus Calibrants
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Table 1 Correlation between GHb results determined from packed cells and from 
whole blood
n Packed 
Cells (x)
Whole 
Blood (y)
y-x
1 9.8 10 0.2
2 5 5 0
3 6.4 5.9 -0.5
4 8.1 7.2 -0.9
5 8.6 8.5 -0.1
6 9.8 9.9 0.1
7 10.8 9.7 -1.1
8 11.2 10.8 -0.4
9 12 11.7 -0.3
10 13.5 13.2 -0.3
11 14.7 13.6 -1.1
12 5.1 4.6 -0.5
13 7.1 6.5 -0.6
14 8.9 8.6 -0.3
15 10.5 10.3 -0.2
16 9.3 8.8 -0.5
17 4.7 3.8 -0.9
18 8.8 7.7 -1.1
19 5.8 5.3 -0.5
20 11.3 10.4 -0.9
21 14.9 14 -0.9
22 8.7 8.1 -0.6
23 5.2 4.9 -0.3
24 7.9 7.7 -0.2
25 10.3 10.1 -0.2
26 7.2 6.8 -0.4
27 8.9 8.2 -0.7
28 11.4 10.9 -0.5
29 11 10 -1
30 8.6 7.9 -0.7
31 9.6 9 -0.6
32 8.3 7.7 -0.6
33 10.5 10.1 -0.4
34 6.3 6 -0.3
35 9.3 9.5 0.2
36 8.7 8.7 0
37 6.2 6 -0.2
38 13 12 -1
39 7.9 7.5 -0.4
40 12.6 11.6 -1
Table 2 Correlation Study of assigned calibrant values of BR1=4.3% BR2=11.3%
n Pierce (x) Drew (y) y-x (y-x/x) XI00
1 17.4 18.2 0.8 4.6
2 11 12.2 1.2 10.9
3 8.5 9.4 0.9 10.6
4 7.4 8.1 0.7 9.5
5 9.5 10.5 1 10.5
6 8.1 8.8 0.7 8.6
7 5.3 5.7 0.4 7.5
8 7.8 9 1.2 15.4
9 7 7.7 0.7 10.0
10 9.3 10.6 1.3 14.0
11 5.8 6.6 0.8 13.8
12 7.6 8.7 1.1 14.5
13 9.1 10.8 1.7 18.7
14 7.3 8.3 1 13.7
15 8.5 9.5 1 11.8
16 11.8 12.6 0.8 6.8
17 4.7 5.4 0.7 14.9
18 8.4 9.1 0.7 8.3
19 7.5 8.3 0.8 10.7
20 9.5 10.9 1.4 14.7
21 4.6 5.2 0.6 13.0
22 8.2 8.5 0.3 3.7
23 10 10.9 0.9 9.0
24 4.2 4.7 0.5 11.9
25 7.6 8.4 0.8 10.5
26 10.2 10.8 0.6 5.9
27 10 11.1 1.1 11.0
28 7.1 7.4 0.3 4.2
29 5.6 6.5 0.9 16.1
30 9.1 10.1 1 11.0
31 7 7.9 0.9 12.9
32 9.4 11.7 2.3 24.5
33 7.7 8.1 0.4 5.2
34 11 11.9 0.9 8.2
35 11.2 10.8 -0.4 -3.6
36 9.4 10.2 0.8 8.5
37 8.7 10.4 1.7 19.5
38 9 10.3 1.3 14.4
39 7.7 8.9 1.2 15.6
40 6.9 7.6 0.7 10.1
41 5.5 6.3 0.8 14.5
42 7.3 8 0.7 9.6
43 8.5 9.7 1.2 14.1
44 8.1 8.6 0.5 6.2
45 6.3 7.2 0.9 14.3
46 6.2 6.3 0.1 1.6
47 9.4 10.9 1.5 16.0
48 10.1 10.9 0.8 7.9
49 11.2 12.6 1.4 12.5
50 5.5 6.3 0.8 14.5
51 8.4 9 0.6 7.1
52 10.8 11.3 0.5 4.6
Table 2 cont.d Correlation Study of assigned calibrant values of BR1=4.3% BR2=11.3%
n Pierce (x) Drew(y) y-x (y-x/x) XI00
53 76 8.5 0.9 11,8
54 8.2 8.8 0.6 7.3
55 6.5 7.6 1.1 16.9
56 9.6 10.3 0.7 7.3
57 11.6 12 0.4 3.4
58 4.7 4.8 0.1 2.1
59 7.2 8 0.8 11.1
60 7.5 8.7 1.2 16.0
61 12 13.1 1.1 9.2
62 8.3 9.4 1.1 13.3
63 9.2 9.8 0.6 6.5
64 9.8 10.7 0.9 9.2
65 14.8 15.2 0.4 2.7
66 9.6 10.2 0.6 6.3
67 7.5 7.5 0 0.0
68 10 10.6 0.6 6.0
69 7.4 7.2 -0.2 -2.7
70 7.6 8.2 0.6 7.9
71 8.7 9.1 0.4 4.6
72 9.1 9 -0.1 -1.1
73 7 7 0 0.0
74 5.2 5.4 0.2 3.8
75 8.2 9.3 1.1 13.4
76 6.5 7.1 0.6 9.2
77 7.2 7 -0.2 -2.8
78 8 8.2 0.2 2.5.
79 13.2 13.6 0.4 3.0
80 6.5 7.5 1 15.4
81 8.7 10.3 1.6 18.4
82 4.5 4.7 0.2 4.4
83 9.5 10.7 1.2 12.6
84 8.3 8.9 0.6 7.2
85 5 5.5 0.5 10.0
86 9.4 10.3 0.9 9.6
87 8.8 9.9 1.1 12.5
88 14.9 16.3 1.4 9.4
89 6.1 6.7 0.6 9.8
Table 3 Correlation Study of assigned calibrant values of BR1=3.8% BR2=10.0%
n Pierce (x) Drew (y) y-x (y-x/x) X100
1 7.6 7.9 0.3 3.9
2 8.4 8.3 -0.1 -1.2
3 8.5 8.2 -0.3 -3.5
4 8 7.6 -0.4 -5.0
5 9.5 9.2 -0.3 -3.2
6 8.9 8.6 -0.3 -3.4
7 6.1 7 0.9 14.8
8 5.5 4.8 -0.7 -12.7
9 10 10.1 0.1 1.0
10 6.3 6.9 0.6 9.5
11 7.3 7.7 0.4 5.5
12 8.6 8.9 0.3 3.5
13 6.7 7.4 0.7 10.4
14 10.8 10.8 0 0.0
15 4.9 5.3 0.4 8.2
16 4.5 4.4 -0.1 -2.2
17 6.6 6.7 0.1 1.5
18 11.5 12.4 0.9 7.8
19 9.8 9.5 -0.3 -3.1
20 6.4 6.8 0.4 6.2
21 9.7 9.7 0 0.0
22 7.9 8.5 0.6 7.6
23 7.5 7.3 -0.2 -2.7
24 7 7 0 0.0
25 10.4 10.4 0 0.0
26 6.9 7.1 0.2 2.9
27 5.3 5.1 -0.2 -3.8
28 6.1 6.4 0.3 4.9
29 12.2 11.4 -0.8 -6.6
30 13.1 13.7 0.6 4.6
31 8.2 8.6 0.4 4.9
32 10.1 11.5 1.4 13.9
33 11 11.5 0.5 4.5
34 11.1 10.9 -0.2 -1.8
35 7.1 6.9 -0.2 -2.8
36 10.2 10.5 0.3 2.9
37 4.9 4.5 -0.4 -8.2
38 9 8.6 -0.4 -4.4
39 7.1 6.7 -0.4 -5.6
40 6.1 5.9 -0.2 -3.3
41 11.1 11 -0.1 -0.9
42 9.6 9.1 -0.5 -5.2
43 7.2 6.9 -0.3 -4.2
44 6 5.7 -0.3 -5.0
45 9.2 9.2 0 0.0
46 8 7.8 -0.2 -2.5
47 5.4 5.3 -0.1 -1.9
48 10.4 10.2 -0.2 -1.9
49 5.4 5.2 -0.2 -3.7
50 10.4 10.6 0.2 1.9
Table 4 Correlation study of Biorad versus Primus Calibrants
n BIORAD (X) PRIMUS (Y) X1>- (Y-X/X) X 100
1 5.2 6.1 0.9 17.3
2 9.6 9.5 -0.1 -1.0
3 8.5 8.5 0 0.0
4 8.1 8 -0.1 -1.2
5 12.5 11.4 -1.1 -8.8
6 6.7 7.1 0.4 6.0
7 13.7 12.3 -1.4 -10.2
8 5.7 6.2 0.5 8.8
9 8 7.9 -0.1 -1.3
10 6.2 6.6 0.4 6.5
11 9.4 9.1 -0.3 -3.2
12 13.9 12.5 -1.4 -10.1
13 10.7 10.1 -0.6 -5.6
14 6.7 7.1 0.4 6.0
15 6.5 6.9 0.4 6.2
16 8.1 8.1 0 0.0
17 5 5.7 0.7 14.0
18 8.8 8.7 -0.1 -1.1
19 13.4 12.1 -1.3 -9.7
20 11.5 10.6 -0.9 -7.8
21 10.1 9.7 -0.4 -4.0
22 8.5 8.4 -0.1 -1.2
23 5.5 6.2 0.7 12.7
24 7.3 7.4 0.1 1.4
25 6.8 7.1 0.3 4.4
26 7.4 7.5 0.1 1.4
27 7.6 7.7 0.1 1.3
28 7.1 7.4 0.3 4.2
29 8.6 8.5 -0.1 -1.2
30 16.6 14.3 -2.3 -13.9
31 10.1 9.4 -0.7 -6.9
32 9.1 8.8 -0.3 -3.3
33 7.4 7.5 0.1 1.4
34 6.5 6.6 0.1 1.5
35 5.8 6.2 0.4 6.9
36 13.1 11.9 -1.2 -9.2
37 7.8 7.8 0 0.0
38 12.8 11.6 -1.2 -9.4
39 5.9 6.3 0.4 6.8
40 6.6 6.9 0.3 4.5
41 5.1 5.8 0.7 13.7
42 7.8 7.8 0 0.0
43 8.7 8.5 -0.2 -2.3
44 11.3 10.5 -0.8 -7.1
45 6.8 7.2 0.4 5.9
46 9.1 8.7 -0.4 -4.4
47 7.9 7.9 0 0.0
48 12.9 11.7 -1.2 -9.3
49 9.3 8.9 -0.4 -4.3
50 11.8 10.9 -0.9 -7.6
51 9.1 8.8 -0.3 -3.3
52 8.3 8.2 -0.1 -1.2
53 6.7 6.9 0.2 3.0
54 5.5 6 0.5 9.1
55 16.9 14.7 -2.2 -13.0
Table 4 cont.d Correlation study of Biorad versus Primus Calibrants
n BIORAD (X) PRIMUS (Y) X1>■ (Y-X/X) X100
56 14.3 12.6 -1.7 -11.9
57 8.4 8.2 0.2 -2.4
58 9.9 9.4 -0.5 -5.1
59 7.3 7.5 0.2 2.7
60 9.6 9.2 -0.4 -4.2
61 6 6.6 0.6 10.0
62 10 9.5 -0.5 -5.0
63 6.9 7.2 0.3 4.3
64 8.8 8.5 -0.3 -3.4
65 6.8 7.2 0.4 5.9
66 5.5 6.1 0.6 10.9
67 9.7 9.5 -0.2 -2.1
68 10.9 10.4 -0.5 -4.6
69 9.6 9.3 -0.3 -3.1
70 6.9 7.5 0.6 8.7
71 .7 7.5 0.5 7.1
72 10.7 10.5 -0.2 -1.9
73 6.6 7 0.4 6.1
74 9.3 9.4 0.1 1.1
75 11.7 10.9 -0.8 -6.8
76 9.6 9.3 -0.3 -3.1
77 14.1 12.7 -1.4 -9.9
78 8.2 8.3 0.1 1.2
79 16.1 14.4 -1.7 -10.6
80 6.5 7.1 0.6 9.2
81 4.8 6 1.2 25.0
82 16.8 15.1 -1.7 -10.1
83 13.2 12.2 -1 -7.6
84 6.6 7.2 0.6 9.1
85 5.2 6.2 1 19.2
86 12.9 11.8 -1.1 -8.5
87 5.9 6.6 0.7 11.9
88 6.8 7.2 0.4 5.9
89 6.6 7.2 0.6 9.1
90 7.3 7.7 0.4 5.5
91 6.9 7.2 0.3 4.3
92 6.4 6.9 0.5 7.8
93 14.5 13 -1.5 -10.3
94 15.9 14.2 -1.7 -10.7
95 9.6 9.3 -0.3 -3.1
96 3.9 5.1 1.2 30.8
97 10.2 9.7 -0.5 -4.9
98 7.5 7.8 0.3 4.0
99 7.2 7.5 0.3 4.2
100 8 8.2 0.2 2.5
101 4.7 5.5 0.8 17.0
102 16.2 14.4 -1.8 -11.1
103 9.6 9.4 -0.2 2.1
104 11.8 11.1 -0.7 -5.9
105 11.4 10.9 -0.5 -4.4
106 5.5 6.2 0.7 12.7
107 13.4 12.1 1.3 -9.7
108 8.1 8.4 0.3 3.7
109 6.8 7.4 0.6 8.8
Table 4 cont.d Correlation study of Biorad versus Primus Calibrants
n BIORAD (X) PRIMUS (Y) Y-X (Y-X/X) X 100
110 4.4 5.5 1.1 25.0
111 8.3 8.5 0.2 2.4
112 7.4 7.7 0.3 4.1
113 7.6 7.9 0.3 3.9
114 8.2 8.4 0.2 2.4
115 9.7 9.5 -0.2 -2.1
116 8.5 8.5 0 0.0
117 10.7 10.3 -0.4 -3.7
118 8.8 8.7 -0.1 -1.1
119 9.3 9.1 -0.2 -2.2
120 4.9 5.8 0.9 18.4
121 5.1 5.8 0.7 13.7
122 10.2 9.8 -0.4 -3.9
123 9.9 9.5 -0.4 -4.0
124 7.7 7.9 0.2 2.6
125 5.1 5.9 0.8 15.7
126 8.3 8.4 0.1 1.2
127 8.4 8.5 0.1 1.2
128 10.8 10.4 -0.4 -3.7
129 4.9 5.7 0.8 16.3
130 4.1 5 0.9 22.0
131 7.4 7.7 0.3 4.1
132 10.1 9.7 -0.4 -4.0
133 7.8 8 0.2 2.6
134 9.2 9 -0.2 -2.2
135 7.3 7.6 0.3 4.1
136 7.2 7.5 0.3 4.2
137 7.2 7.5 0.3 4.2
138 5.5 6 0.5 9.1
139 9.6 9.4 -0.2 -2.1
